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ABSTRACT OF THE THESIS
DETECTION AND NEUTRALIZATION OF BACTERIAL BIOHAZARDS VIA
NANOENCAPSULATION
by
Rosaura De Zayas
Florida International University, 2007
Miami, Florida
Professor Eric T. Crumpler, Major Professor
Bacteria biohazards, such as Anthrax, are responsible for causing mild to serious
illnesses in humans and animals. The primary aim of this research study was to develop a
rapid one step assay to detect and neutralize bacteria-based biohazards, using an
Immunoliposome-nanoparticle complex. An Anthrax model, Bacillus cereus, was grown
for 3 hours and diluted 1:25 in media (2.0 x 107 cfu/ml). The Bacillus cereus was
interacted with an Immunoliposome-nanoparticle complex containing an MgO-C 2,
neutralization agent. The samples were analyzed via flow cytometry with a 1:8:1 ratio
Bacillus cereus, Immunoliposome-nanoparticle complex, and Ethidium homodimer-1 for
two hours. The results obtained showed when the Immunoliposome-nanoparticle
complex were interacted with bacteria both detection and neutralization occurred
immediately. As incubation time increased, fluorescence shifted closer to the control
region. Therefore, bacteria can be immediately detected with the Immunoliposome-
nanoparticles complex, and high levels of neutralization can be achieved less than two
hours of incubation.
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1.0 INTRODUCTION
Bacteria biohazards are found in various everyday surfaces and are responsible for
causing mild to serious illnesses in humans and animals. These bacteria biohazards are
found in drainage pipes, sinks, air conditioning systems, and on any surface that provides
a nutrient environment for bacteria proliferation'. These bacteria community sites are
referred to as bacteria biofilms. The treatment and detection of these biofilms, or of any
bacteria biohazards like anthrax, are of great concern for its abrupt catastrophic effects.
The crucial need to rapidly identify and neutralize these pathogens for both the private
and military sectors is of great importance; especially with current heighten awareness of
the possible implications that could arise with the use of biological weapons.
One main obstacle in the detection and neutralization of bacteria is the lapse of time
needed to identify the pathogen before severe irreversible illness occurs and the survival
of the patient is jeopardized. For example, positive identification of Bacillus anthracis
requires 24-48 hours. If unidentified within this time period, this particular pathogen may
have already progressed to the lethal phase. Once the lethal phase has been reached, the
possibility of patient survival becomes slim. The inability to successfully identify this
bacteria in a timely manner needed is the reason why biological agents such as anthrax
are extremely effective as biological weapons. The lethal effectiveness of these agents
when used in bio-terrorism makes it imperative to develop a novel assay that aims to
rapidly detect and neutralize bacterial pathogens.
At this current moment, detection methods for bacteria involve the use of
microbiology assays such as Polymerase Chain Reaction (PCR)2 . This assay functions by
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replicating the DNA of an unknown pathogen in order to identify bacteria or viruses.
Several illnesses are identified by this technique, ranging from infectious diseases to
hereditary illnesses. Unfortunately the PCR assay long procedure creates a problem for
identifying specific bacteria species, and the detection and identification of the precise
pathogen may not occur within the time needed 3.
On a broader spectrum, bacteria biofilms contain various bacterial species. Current
treatments for these biofilms involve the use of very high doses of drug containing
detergents, with high levels of chlorine. These detergents are highly effective, but
pathogenic drug resistance occurs over time. The presence of biofilms in buildings has
led to the classification of Sick building syndrome. Because detecting the bacteria or
fungi is extremely difficult, ere are limitations in treating these buildings. Currently, a
new detergent called, biocide containing chlorine dioxide in a gaseous form, is being
investigated to treat bacteria contamination4 . Although, detergents such as this have been
found to be highly successful in eradicating bacterial pathogens, one main problem still
remains; the inability of identifying these pathogens in the time needed. In many cases
once this treatment has been administered, a typical illness outbreak has already occurred.
Additional emphasis has been focused towards the treatments of sick buildings. The
growing number of sick buildings have been attributed to closed ventilation, which has
led to high prevalence of bacterial biohazards5 . For this reason, current studies are being
performed to address this issue. The ideal treatment candidate should be an applicable
single step identification method that can be used to cure these sick buildings.
Unfortunately, progress in developing methods for detection and neutralization of
biohazards has been gradual. Currently, there are no topical assays that can be sprayed
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on a surface that can instantly detect and neutralize bacterial-like biohazards. Since time
is a critical factor when dealing with hazardous life threatening substances, the inability
to quickly determine the presence of pathogens has been a topic of interest since the
events in the United States on September 1 1th, 2001. In the event of a biological attack, it
is imperative that the pathogen be identified and neutralized both rapidly and easily.
The new detection and neutralization assay proposed could be administered to detect
the presence of bacteria, specifically bacillus species. The neutralization section of this
assay has incorporated liposomes, shown to be efficacious in various drug-delivery
applications6. These liposomes contain targeting ligands that are highly specific to some
bacterial species. As a result of incorporating these liposome's with a newly synthesized
neutralization agent, MgO-Cl2 we should expect to eradicate these bacteria pathogens
quickly and effectively. In addition, the incorporation of fluorescent nanoparticles to
these liposomes will enable the presence of bacteria to be detected prior to neutralization.
This new assay aims to immediately detect and neutralize bacteria-like biohazards in any
environment.
1.1 Research Objectives and Specific Aims
The primary aim of this research study was to develop a rapid one step assay to
detect and neutralize bacteria-like biohazards using an Immunoliposome-nanoparticle
complex. This complex has the potential to be administered on any surface and allow a
quick notification and eradication of bacteria biohazards.
Neutralization of bacteria biohazards were enhanced by using liposome drug
carriers encapsulated with a neutralization agent (MgO-C1 2 ). Detection of bacteria was
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conducted by incorporating fluorescent nanoparticles to polyclonal antibodies. The
combination of both the detection and neutralization portion of the assay, results in a one
step detection and neutralization assay for bacteria-like biohazards. The aims of this
study were optimized to enhance bacterial detection and decrease neutralization time in
an in-vitro environment. The specific aims of the study were as follows:
1. Create 100 nm liposome size solution with high concentration of a neutralization
agent MgO-C12
2. Surface modification of the liposome in creating immunoliposomes attached to
fluorescent 40 nm Streptavidin coated nanoparticles
3. Perform bacterial and Im muoliposome-nanoparticle complex interaction
live/dead verification test.
1.2 Significance of the Study
This research study is significant because it will first; attempt to develop a new
procedure to fluorescently detect the presence of bacteria biohazards. Secondly, create a
novel drug-delivery technique to neutralize bacteria biohazards by using liposomes with a
newly developed neutralization agent, MgO-C 2, and formulate various lipid formulations
to determine an optimal release of the encapsulatant neutralization agent, MgO-C1 2.
Finally, develop a one step application that will detect and neutralize bacteria by using
the Immunoliposome-nanoparticle complex that can be applicable on any surface to treat
against bacteria cells and bacteria biofilms.
2.0 BACKGROUND
The events surrounding September 11 ih heightened the awareness of the possible
implications of using anthrax as a biological weapon. Since the 1900s, very few cases of
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anthrax have been recorded in the United States. This increased in 2001, when twelve
cases were reported, all of which, occurred in U.S. Government offices7. The sudden
prevalence of hazardous infections heightened the publics' awareness of anthrax
becoming the new weapon of choice.
Biological weapons have been a source of concern decades before September 11.
The United States experimented with biological weapons, including anthrax, from 1950
to 1960. In 1970, the world health organization published a report stating the possible
devastating effects of an anthrax attack. In this report it was stated that if 50 kilograms of
aerosolized Bacillus anthracis spores were disbursed from an airplane two kilometers
upwind of a population center of 500,000 in ideal meteorological conditions, the spores
would travel a distance greater than 50 km and kill approximately 95,000 people. The
economic effect of such an attack would be approximately $26 billion per 100,000
persons exposed8 . These findings illustrate the gravity of the impact of an Anthrax
attack. Anthrax, however, is not the only possible biological agent available to bio-
terrorists. There is a long list of other lethal bio-agents that can be used to cause similar
catastrophic situations. For this reason, a new neutralization and detection method that is
not species specific is in great demand.
2.1 Bacteria
2.1.1 Bacillus anthracis
Bacillus anthracis is a large, gram-positive aerobic spore forming bacteria that
measures 1.0-1.5 pM by 3.0 to 10.0 [M. Unlike other saprobic species (B. subtilis and
B.cereus), Bacillus anthracis is non-motile7 . It grows readily at 37*C and forms large
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colonies with irregular tapered outgrowths'. In-vitro, it grows in long chains, but in hosts
it appears as a single organism or chains of two or three bacilli. These bacterial cells
form mucoid colonies and exhibits prominent capsules when grown in nutrient agar'.
One of the characteristics of Bacillus anthracis is the ability to form a protective
capsule when deprived of nutrients. This protective capsule is the primary indication of
bacterial cell transformation into a spore. When the spores are formed, they can survive
centuries in soil or in other organisms. Naturally, B. anthracis spores do not form in host
tissues unless body fluids are exposed to ambient air. B. anthracis germinates when
exposed to nutrient-rich environments, such as the tissue or blood of an animal or human
host. Anthrax longevity, virulence and adaptability make it an ideal candidate as a bio-
terrorism agent.
Figure 1. Bacillus anthracis9
2.2 Epidemiology of Anthrax
Understanding the mechanism by which anthrax operates is extremely important
when attempting neutralization. Anthrax is subdivided into three clinical types:
Cutaneous anthrax, Inhalation anthrax, and Gastrointestinal anthrax.
Cutaneous anthrax constitutes more than 95% of naturally occurring anthrax. It is
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commonly found in soil and usually infects individuals handling livestock in developing
countries'. Infection initially occurs when the anthrax spore enters a cut or abrasion in
the skin. The following day after infection, a papule forms around the endospore, the
papule vesicle develops further, and edema in that vesicle starts to increase. At this stage
of the illness low fever occurs, and the vesicle begins to undergo necrosis. Next, the
vesicle ruptures forming an ulcer covered by a black eschar, which falls off after two
weeks leaving behind little sc ing7. These symptoms appear within one to seven days
following infection. This type of anthrax is treatable, but without antibiotic treatment for
mortality is approximately 20 percent.
Inhalation anthrax, the most lethal type of anthrax, attacks into two phases. Once
the anthrax spores are inhaled, they travel immediately through the upper airways to the
lungs. The spore size is approximately 2 tm, making it possible for the spores to reach
the alveolar ducts and alveoli within the lungs. Once entrance into the lungs, they trigger
an immediate immune response. Macrophages engulf the spores, and then transport them
to the lymph nodes. This occurs in phase 1 of the illness, usually within a time period of
24-48 s following infection. At this time, an overwhelming concentration of toxins
begins production by the spores, within the lymph nodes, and enters the systemic
circulation where edema, hemorrhage, necrosis, and septic shock occur; usually resulting
in the death. This is the second phase of the illness that occurs between 2 to 6 days
following infection8 .
Gastrointestinal anthrax is a subcategory of the anthrax illness, occurring upon
ingestion of meat products infected by spores. Usually, symptoms associated with this
illness occur two to five days after contaminated food has been ingested. The first
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symptom the patient may often experience is throat pain or difficulty swallowing. As the
illness progresses, patients experience additional symptoms, such as sores in the mouth
and throat, severe bloody diarrhea, and intestinal lesions7 . Due to the similarity of
symptoms in other illnesses, gastrointestinal anthrax has a very high mortality rate.
Arlhrax enters thru skin Enters thru intestines Enters thru lungs
a.t
Leads to locs edema Massive outpouring of ruptured
and necrotic (dead vessels, rnucosal edema and
tissue) lesions necrotic (dead tissue) lesions
Mac~erophege
Anthrax bacillus ' 'K4
Factors Affecting Virulencis
capsule -
Exoto>dns
Other Factors
Regional Lymph Node
Inflammation and bleeding
in lymph system
Spreads to lymph
and blood syste Invadespoisons blood Lung and
Meningitis lymph blockage
7'N Y'ret inthe lungs
Shock
Death 4 Death Death
Figure 2. Pathways of the types of Anthrax10
2.1.2 Bacillus Cereus
Bacillus cereus is well defined as a rod shaped, gram positive spore forming bacteria,
which is resistant to high temperatures". These spores occur naturally in most foods, and
have been linked to a wide range of illnesses ranging from blindness to food poisoning.
The food poisoning illness have been subdivided into two specific types, an emetic illness
or a diarrhoeal illness". Emetic illness occurs 1-6 hours after ingestion of contaminated
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food containing pre-formed toxin, with symptoms of nausea and vomiting 1 . The
diarrhoeal symptoms are attributed to the ingestion of vegetative organisms or spores.
Subsequently multiplication and toxin production within the intestinal tract, result in
abdominal pain, watery diarrhea and occasional nausea". The intraocular infection
associated with B. cereus has been known to cause necrosis and potentially blindness
within 24-48 hours12 .
The genetic similarity between B. cereus and B. anthracis has allowed B. cereus to be
used as an effective model for Anthrax. The use of this Anthrax bacterial model provides
a platform for development of drug treatments against the deadly pathogen. Although the
severity of Bacillus cereus strain is not on the level of B. anthracis, B. cereus is well
armed with weapons capable of damaging or exacerbating damage to human and animal
tissue. One of the factors preventing B. cereus from becoming an aggressive human
pathogen is its lack of the protective mechanism against an intact immune system.
Although B. cereus is not considered as hazardous as anthrax it has still been known as a
serious health concern in developing countries.
2.1.3 Bacillus Genus Similarities
Within the genus of Bacillus, there are other bacteria that exhibit characteristics
similar to those of Bacillus anthracis (B. anthracis); including Bacillus cereus (B.
cereus), Bacillus thuringiensis (B. thuringiensis), and Bacillus subtilis (B. subtilis). It is
speculated that B. cereus was the ancestral bacteria specie that underwent evolutionary
mutations within the genetic material giving rise to other types of bacteria species, such
as B. ant hracis and B. thuringiensis3 . The genetic characteristics of Bacillus
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thuringiensis and Bacillus cereus are almost indistinguishable, making them the closest
bacterial relatives 2 . Moreover, the genetic or virulence factor of Bacillus thuringiensis
can be transferred to B. cereus bacteria and inevitably transform B. cereus into B.
thuringiensis. The only established difference between these two bacteria species is the
presence of genes, found on plasmids, coding for insecticidal toxins.
B. cereus and B. anthracis are almost indistinguishable from one another. Close
similarity of the genomes of B. anthracis strains to those of B. cereus and B. thuringiensis
strains demonstrate that they originated from the same species. What distinguish these
bacteria from one another are the genes carried on the plasmids, as well as the virulence
factors found in B. anthracis. For example, the distinctive characteristics of B. anthracis
such as sensitivity to p-lactam antibiotics, lack of motility, and hemolytic activity may be
caused by a difference of a single gene found in B. cereus13. Also, PlcR, a transcriptional
regulator of extracellular virulence factors in both B. cereus and B. thuringiensis, has been
found mutated in B. anthracis strains'3 . The severity of this mutation can be partially
responsible for some of the features often associated with B. anthracis, such as lack of
hemolytic activity. Because of the biochemical and physiological similarities between
them it is possible to use B. cereus and B. subtilis as a model for anthrax
2.1.4 Virulence factors of B. anthracis
The virulence factors of Bacillus anthracis are produced in two specific plasnids;
PX01 and PX02 4 , each encoding for specialized proteins with a specific function. PXOI
produces a protective antigen protein, an edema factor protein, and a lethal factor protein.
The protective antigen protein protects the Anthrax spores, while the edema factor
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protein is responsible of causing edema in the infected area on the organism. The lethal
factor protein functions by blocking receptors that would typically be recognized by the
immune system. The combination of these proteins, referred to as the toxin complex, is
responsible for patient death14 . The second plasmid, PXO2, encodes for proteins required
in the biosynthesis of protective polypeptide capsules which function by inhibiting
immune system responses
2.2 Biofims
A Biofilm is a community of bacteria, fungi, yeasts, protozoa, and other
microorganisms attached to a solid surface. Due to the susceptibility to surfaces that
provide adequate nutrients for microorganisms to grow', biofilms pose a great threat and
are attributed to a variety of widespread illnesses.. Biofilms have been found in
numerous areas, such as medical devices, and household common areas including sinks
and PVC pipes".
Otitis media, which is the most common acute ear infection in children, is one
illness in the U.S associated with biofilms. Other diseases include bacterial endocarditis
(infection of the inner surface of the heart and its valves), cystic fibrosis (a chronic
disorder resulting in increased susceptibility to serious lung infections), and Legionnaire's
disease (an acute respiratory infection resulting from the aspiration of clumps of
Legionnella biofilms detached from air and water heating/cooling and distribution
systems). The degree of severity of illnesses caused by biofilms, can be more critical
then others depending on location. For example, in hospitals, biofi -related infections
can include the surfaces of catheters, medical implants, wound dressings, or other types
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of medical devices. In patients whose immune system has been comprised, biofi s can
lead to life threatening consequences, due to the antibiotic resistance. Usual treatments
for biofilm infections require a long-term dosage for eradication.
Another sector greatly affected by Biofims, are manufacturing industries, where
billions of dollars in productivity and capital equipment are lost each year 1. Its presence
in pipes has been known to cause severe corrosion and water contamination.
Currently, in the prevention of biofihm formation, treatment for surface coating
requires the use of cocktails of drugs. Vancomycin is a drug often used to treat infections
that occur on medical catheters"5 , due to the frequent occurrence of methicillin-resistant
coagulase-negative staphylocci, including S. epidermis. The effectiveness of treatments
such as this are compromised if biofilm formation occurs during dr treatments.
Biofi s drug resistance is attributed to its changes in cell wall and surface structure.
Therefore, non-specie specific treatments that can effectively eradicate biofims quickly
are in great demand.
2.3 Sick Building Syndrome
Sick building Syndrome (SBS) are classified as building that have been known to
contribute to several health issues, including upper respiratory symptoms, headaches,
fatigue, and rash which are usually associated with a particular building by there temporal
pattern of occurrence and clustering among inhabitants or colleagues experienced
everyday5 . The prevalence of closed ventilation and aged buildings has increased the
occurrence of illnesses classified as sick building syndrome. The severity of these
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illnesses range from common colds to more severe respiratory illness, all of which have
been attributed to the closed air ventilation system within buildings that allow indoor air
contaminants to build up 6 .
Since the 1970s, closed ventilation systems have increased worldwide to decrease
energy consumption. The effect of decreasing energy consumption has lead to high
prevalence of illnesses and higher susceptibility of hazardous molds and bacteria 6 . The
most common bacteria found in indoor environments include Bacillus, Pseudomonas,
Staphylococcus, Micrococcus, Methylobacterium and Flavobacterium'. The widespread
accumulation of bacteria within the human body has been the primary means of
dispersing bacteria.
Many bacterial and fungal species are isolated in indoor air, due to there
dependence on a nutrient source, water availability, relative humidity, and temperature,.
Sources of micro-organisms in indoor air include: cooling towers, water damaged
materials, high humidity in indoor areas, damp organic material and porous wet
surfaces'. The porous wet surfaces provide a favorable environment for biofilm
formation'.
These biofi s, composed of populations or communities of microorganisms
adhering to environmental surfaces, are found on essentially any environmental surface in
which sufficient moisture is present. Their development is most rapid in flowing systems
where adequate nutrients are available. Current treatments for sick buildings require the
use of a chlorine detergent, but these detergents are being examined for there effectiveness.
Therefore, new modalities are being pursued to cure these sick building.
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2.4 Current methods of detecting anthrax
Traditional detection methods requires the growth of single bacteria into bacterial
colonies in different types of media, followed by a lengthy identification process
involving morphological and biochemical tests1 9. All of these procedures often provide
very accurate results, but suffer from poor specificity. Additionally, they often require
complicated interpretation with complete analysis time, typically approaching 72 hrs,
making them unsuitable for online rapid analysis3. Recent efforts have been directed
towards developing approaches suitable for the entrapment or capture of bacteria, based
on a combination of physic characteristics of the capturing medium and the affinity of
the bacteria for a variety of chemical ctionalities, While rapid, these methods are
nonspecific, requiring completion of multi-step analysis for identification and
quantification.
Most commonly available assays for the detection of spores or bacteria involve the
use of enzyme-linked immunosorbent assays (ELISA). This assay functions by using
antibodies or antigens coupled to an enzyme that possesses a high turnover number' 2
ELISAs can provide a useful measurement of antigen or antibody concentration by
demonstrating high specificity and reproducibility. A drawback of this method is it is
usually a lengthy analysis process that is not suitable for real-time analysis.
A large amount of efforts have been made recently to decrease analysis time and
improve sensitivity and selectivity through the application, modification, or combination
of various techniques. Currently, Polymerase Chain Reaction (PCR) and fluorescent
antibody staining are the two main detection methods utilized to detect B. anthracis.
PCR is commonly used to replicate the genetic information to identify pathogens. The
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problems with both PCR and Fluorescent antibody testing is that they require culturing
samples taken from the patient before it can be identified, this typically takes 24-48 hrs2.
After the sample is grown, a standard PCR test is performed. PCR, however, is not very
sensitive to anthrax. Once the suspected stain is identified more vigorous testing is
performed to positively identify anthrax. Other drawbacks include difficult sample
preparation, long analysis time, the need for trained personnel, high reagent costs,
potential contamination, false positives, and poor adaptability to multiplexing 3.
2.5 Current treatment of anthrax
Antibiotics are the current treatment used to fight anthrax infections. The typical
antibiotic treatments that are Center for Disease Control (CDC) approved include
ciprofloxacin, doxycycline, penicillin, and multiple antibiotics21. In the case of inhalation
anthrax or systemic involvement, the CDC recommends the use of multiple antibiotics.
One main issue in the actual treatment of anthrax is that the bacterium needs to be
identified before treatment can be administered. Currently, positive identification of B.
anthracis is a lengthy process, which can take up 48 hrs, and the only facilities capable of
detecting anthrax are the CDC laboratories. Delays in identification of anthrax are due to
similarities between B. anthracis and B. cereus. Hence, the mortality rate of 99 percent
associated with inhalation anthrax is mainly due to late identification and failure to
administer treatment during the early phase of infection.
2.6 New neutralization agent for Bacteria strains
Nanomaterials are considered advanced materials that can be used for the
decontamination of chemical and biological warfare agents. Nano-size metal oxides have
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been shown to be reactive absorbents of chemical and biological warfare agents Nano-
size Magnesium Oxide (MgO), Calcium Oxide (CaO), and Zinc Oxide (ZnO) have been
shown to possess strong antibacterial properties that can be used to absorb biohazardous
materials Among these metallic oxides, MgO and CaO act upon both Gram-positive
and Gram-negative bacteria in a bactericidal manner. On the other hand, ZnO displayed
a stronger antibacterial activity against gram-negative bacteria. It has also been found
that the addition of C12 to MgO forms a new molecule called Magnesium oxide chloride
(MgO-Cl2), which is highly reactive and absorbs more bacterial agents. It exhibits high
activity against bacteria, spores, and viruses2.
2.6.1 Properties of MgO/MgO-C1 2
MgO nanoparticles have a large surface area with an abundance of unusual crystal
morphologies, posing numerous edges/corners and other reactive sites2 5 . These porous
nanoparticles have the ability to adsorb and retain significant amounts of elemental
chlorine and bromide for long periods of time25 . Moreover, these MgO-Cl 2 nanoparticles
have been shown to be quite active biocides, more than free Cl 2 or MgO alone25 .
MgO-C2, positively charged particles, reacts with negatively charged bacteria
and spores. The opposite charge attraction between bacteria and nanoparticle reveals one
reason for the tight binding of nanoparticles to the bacteria surface. Due to the strength
of both nanoparticle bacteria binding and neutralization properties of the nanoparticles,
studies have shown significant cell envelope damage after 20 minutes of nanoparticle and
K coli bacteria incubation. Moreover, when this treatment was applied to B. subtilis
spores similar destructive results were found. When images were captured after MgO-
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Cl2 were incubated with B. subtilis spores, visible "holes" in the cell wall were seen2.
Both the damage to the cell envelope and holes in the spores indicated bacteria death25 .
For this reason, MgO-C 2 has shown promising ability to neutralize more bacterial agents
in less time.
In addition, it has been found that smaller MgO nanoparticles are more efficient in
neutralizing bacteria2 6 . The distribution and the interaction among these particles result
in a crystalline cluster, which cover the bacteria cells. This results in bringing the
halogen reagent to an active form in high concentration within the proximity of the cell25 .
Thus, smaller MgO-C1 2 nanoparticles can eradicate the bacteria faster and more
efficiently.
2.7 Liposomal Technology
The mechanics of liposome drug-delivery systems can be modified to meet
different needs. The drug concentration can vary among the different type of liposomes.
Liposomes can be subdivided into three specific categories as follows:
1. Multilamellar vesicles
2. Small Unilamellar Vesicles
3. Large Unilamellar Vesicles
The differences between the types of liposome are due to the different processes
used to create them. Each type of liposome is completely dependent on its drug delivery
application.
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There are many advantages of using liposomes in drug delivery. One advantage is
the liposomes ability to carry high concentrations of drug relative to their size. Another
advantage of liposomes is their ability to be modified with tracers and/or antibodies to
assist in reaching their target. The surface of liposomes can be modified through the
attachment of protein, peptides, nanoparticles, and antibodies via a PEG linker chain 7 . It
has been found that functionalization on the PEG group creates steric hindrance with the
antibodies, thereby interfering with target site recognition 2 . Therefore, modifications via
co-enzymes attached to PEG-liposomes are currently being used to prevent the steric
hindrance and increase the possibility of liposomes to bind to their target site.
2.8 Liposome Composition
Liposomes are composed of hydrophobic chains and hydrophilic head groups forming
a lipid bilayer. The polar head groups are oriented to the solution and within the inner
cavity. The functionalized polar head groups are used to reduce liposome aggregation,
and the hydrophobic regions are used to modify the properties of the liposome' . The
phospholipid concentration can vary to achieve positively or negatively charged
liposomes depending on which of the numerous advantages it is needed for in drug
delivery. The addition of Cholesterol within the liposome membrane is often used to
reduce membrane permeability to the encapsulated materials, creating a
phospholipids/cholesterol ratio to mimic the makeup of a cell membrane. Cholesterol
diverse function in membrane stability plays a vital role in the release of the encapsulated
material. Therefore, the interaction between lipid membranes and biomolecules can be
measured using liposome drug delivery.
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2.8.1 Types of Processes to Create liposomes
The three categories of liposomes are determined by the experimental procedure
used to create them. Large Multilamellar Vesicles (LMV) are formed when films sheets
are hydrated, and the films detach during agitation and self-close 31 The size distribution
of the LMV sample is around several microns3. The LMV size distribution is attributed
to the rehydration of the lipid sheets, and the self-closure of the liposome vesicles.
When these LMVs are probe sonicated for an hour it results in the formation of
Small Unilamellar Vesicles (SUV). The size range of the SUV liposomes range with
diameters less than 40 nm3 2 . The SUV have been shown to attain a smaller aqueous
cavity within the lipid bilayer. These SUV have the ability of being further processed to
create large unilamellar vesicles.
The SUV vesicles can be circulated through specific pore size filter membranes to
create size specific Large Unilamellar Vesicles. These Large Unilamellar Vesicles
(LUV) are the last type of liposomes that can be created after SUV. These LUV
liposomes are created by an extrusion process, by which LMV solution is circulated
within an extruder apparatus assembled with a size defining filter membrane. These filter
membranes can be purchased with various pore size determining on the specific liposome
size desired.
These LUV liposomes have a large aqueous cavity that provides high drug
encapsulation. For this specific reason LUV has been favorable for a variety of different
drug delivery procedures. The specific qualities of these liposomes are the ability for
them to carry a high drug to lipid concentration within the aqueous cavity. A detailed
visual liposome pathway is shown below.
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Figure 3. Liposome Pathway3 1
2.8.2 Trehalose Lycoprotectant
Trehalose is a disaccharide molecule that serves as lycoprotectant during freeze-
drying. Its lycoprotectant properties can be characterized into two processes; Glass
formation and Interaction with phospholipids. During sugar glass formation an
amorphous matrix is formed between liposome vesicles 3.
Figure 4. Function of Trehalose with liposomes3 1
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2.9 Streptavidin - Biotin interaction
Biotin is a co-enzyme, which functions by transferring carbon dioxide into
substrates. It is a naturally occurring vitamin found in eve living cell. Avidin is a
glycoprotein whose function is to block the activity of two carboxylating enzymes,
characterizing them as biotinyl enzymes33 . Streptavidin is a biotin-binding protein
isolated from culture broth of Streptomyces auidinii .
Avidin and Streptavidin share common properties, as they are both tetrameric
proteins with four sites available for biotin to bind to. The binding ratio recognized is 1
mole of biotin for eve 14,000 g of streptavidin. Thus, the interactions amongst these
two molecules are extremely high. Biotin interaction with avidin or streptavidin is
among the strongest non-covalent affinities known, exhibiting a dissociation constant of
about 1.3 x 10-1 34.
Bioconjugation technique assays favor streptavidin protein, since an overcoming
unspecific binding that occurs with avidin. This is owed to avidin's basic isoelectric pH
(pI) of 5-6 compared to streptavidin's pI of 1034. The Differences in p are due to the
variations in the amino acid sequence in the proteins. Those differences do not affect the
interactions with biotin, which is still very strong. Even in the presence of buffers and
under acidic conditions, bond dissociation does not occur.
The biochemical reaction between avidin and biotin has been monitored using
fluorescent microscopy and flow cytometry by attaching fluorescent nanoparticles to
these molecules. The use of nanopa icle coated streptavidin is most useful in imaging,
due to its interaction with biotin.35 The fluorescent properties of the nanoparticles
interaction with bacteria are easily identified through flow cytometry 36
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2.10 Antibody
An immunoresponse is triggered by the production of antibodies called
immunoglobulins. These antibodies all have the same basic similar structure of four
polypeptide chains: two light chains and two heavy chains joined together by disulfide
bonds, with an end result Y shape. Within the structure of the antibodies there are
specific binding sites where it binds to an antigen specific epitope37.
Antibodies are classified under two categories, depending on epitope recognition37 .
These two types of categories are Monoclonal and Polyclonal. The monoclonal
antibodies are highly specific; only bind to one antigen site. On the other hand, the
polyclonal antibodies can bind to many different sites on the antigen.38 The use of
different types of antibodies depends solely on the application.
2.11 MgO-C1 2 Verification Testing
2.11.1 Presence of Chlorine in MgO-C 2 nanoparticles
Silver nitrate (AgNO 3) is a chemical used to test the presence of halide ions.
Since MgO-C 2 has chloride ions, the reaction with Silver Nitrate should result in a color
change of a white precipitate. If several drops of 0.1 M AgNO 3 is added into an unknown
solution, the solution will immediately produce a white precipitate in the presence of
chloride, bromide, and iodide. A reference list of the reaction of AgNO 3 with halides in a
solution is noted in the table below. Note, a color change is a result of the exact halide
presence (refer to Table 1.)
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Halide Ion Observation with Silver Nitrate
Chloride White precipitate forms
Bromide Cream precipitate forms
Iodide Yellow precipitate forms
Table 1. Silver Nitrate Reactants and Color Observation
2.12 Liposome and Antibody Purification
2.12 Size Exclusion Chromatography
Size exclusion chromatography (SEC) is a widely used technique for separating
impurities in samples. SEC is composed of porous particles (beads) that separate
molecules based on their particle sizes and molecular weight. It is often used to separate
biological molecules that are smaller than the pore size, that can enter the beads, while
larger molecules are not retained in the beads and are eluted39. A variety of sizes of the
sephadex beads are used for different purifications based on molecular weight, so that the
unwanted material will be retained within the sephadex beads and the purified final
sample is eluted.
2.13 Antibody and Streptavidin Nanoparticle Synthesis Yield
2.13.1 Protein Concentration using Spectrophotometer
The Tecan Genios Spectrophotometer measures the absorbance of the proteins in
within a sample, in order to determine the concentration in the solution.
Spectrophotometers functions by measuring the light absorbed or transmitted by
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molecules in solution using the beer-Lambert law. When a specific light wavelength is
transmitted through the solution, the light energy absorbed [absorbance (A)] is
proportional to:
1. The ability of the solute molecules to absorb the wavelength
2. The concentration of the solute
3. The length of the light path from its source through the solution to the
phototube where the percentage of light energy transmitted or absorbed is
measured.
The spectrophotometer absorbance readings are used to determine the
concentration of protein in an unknown sample. By implementing the experimental
reading within an equation you can theoretically determine the protein concentration
(mg/ml) within a solution. The equation is as the follows:
Concentration (mg/mi)= (1.55 x A280) - 0.76 x A260) 40
2.13.2 BCA Assay
Bicinchoninic acid protein assay (BCA) has become the most popular
colorimetric detection d qu ti tion assay for protein'. This assay combines the well
known reduction of Cu2+ to Cul in the presence of protein in an alkaline medium,
producing a highly selective colorimetric deter ion of the cuprous action by bicinchoninic
acid4 2 . The protein is reacted with copper through a process of chelation, resulting in a
blue colored solution. The biuret reaction occurs with the chelated protein giving a blue
and violet color solution that absorbs light at 540nm. Since the working range for the
biuret assay is from 5 to 160 mgl, the bi et assay is used in clinical laboratories for
42R
the quantitation of total protein in serum
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2.14 Bacteria and Immunoliposome-nanoparticle Complex Testing
2.14.1 Flow Cytometry
Flow cytometry is a technology that measures and analyzes multiple physical
characteristics of a single particle as they flow in a fluid stream through a beam of light.
The optical properties measure the particle size and relative fluorescence intensity. In the
flow cytometer, particles are carried to the laser intercept in a fluid stream, where the
particles pass through a laser intercept, scattering light. When fluorescent particles are
present they are fluoresce. Both the scatter and the fluorescent light are collected and are
transformed into data displays43.
2.14.2 Bacterial Cell Viability
Bacteria cell viability can be determined by various techniques such as dilution
method and fluorescence. Fluorescence testing is currently the fast method to determine
if a bacteria culture is viable. These assays vary by the binding site of these fluorescent
probes, such as DNA, cell membrane, and cellular respiration. The high specificity of
fluorescence detection has made it a desirable assay for determining quantitative
interactions among dyes, as well as displaying other interaction not possible by
traditional methods 4.
2.14.2.1 Ethidium homodimer-1
Among the fluorescent dyes, Ethidium homodimer-1 is used to identify dead
bacteria cells. This dyes functions by binding to the DNA of bacteria cells that have been
comprised emitting a deep read color. Since this dye is impermeable, the fluorescent
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signal is only achieved upon DNA binding. For this reason, Ethidium homodimer-1 is
widely used to obtain a quantitative bacteria cell count of membrane-comprised cells by
using Flow cytometry or Fluorescent Microscopy45
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Figure 5. E thidium homoimer-1 fluorescent spectrum4
2.14.2.2 Syto-
Syto-9 is a green fluorescent dye that binds to cells with both intact -membrane and
disrupted membranes to determine if the bacteria cells are alive. The fluorescent property
of Syto-9 is observed at excitation/emission 480/500nn that emits agreen fluorescence.
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Figure 6. Syto-9 Fluorescent spectrum45
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3.0 MATERIALS AND METHODS
3.1 Materials
3.1.1 Neutralization Agent
The neutralization agent, MgO-Cl 2 nanop tiles, were synthesized and analyzed
by Nanomat Inc. The product information attained from Nanomat Inc, stated that these
nanoparticles were approximately 5 nm in diameter and contained 4-5% Chlorine per
weight.
3.1.2 Liposomes
The Liposome lipid materials were purchased from three companies, Northern
Lipids, Avanti Polar Lipids, and Sigma-Aldrich. The first functional lipid, Biotin-DSPE
was purchased from Northern Lipids, and the second functional lipid, Biotin capped-
DSPE-PEG2000 and Cholesterol, were purchased from Avanti Polar Lipids. The
Phosphatidylcholine (PC) lipid was purchased from Sigma-Aldrich. All these lipids were
dissolved in ACS graded reagent Chloroform purchased from Fisher Scientific.
The lipid films were all reconstituted in HEPES buffers purchased from Gibco,
and were circulated through a Mini extruder Apparatus with 100 n filter supports and
membranes purchased from Avanti polar lipids to create liposomes. Liposome
purification was performed with Sephadex G-50 purchased from Sigma Aldrich.
3.1.3 Antibody-Streptavidin Coated Nanoparticle complex
The polyclonal antibody for B. anthracis was purchased from biodesign, and was
chemically modified with a crossli er, 2-Iminothiol e (Traut's Reagent) purchased
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from Sigma. After modification, the intermediate product was purified using Sephadex
G-25 purchased from Amersham Biosciences.
The 40 nm streptavidin coated fluorescent nanoparticles were purchased from
Fluka, and chemically modified with a specific crosslinker, m-Maleimidobenzoyl-N-
hydroxysuccimide ester (MBS). After nanoparticle site modification, the sample was
purified with a centriprep 30-ultrafiltration device purchased from Millipore.
3.1.4 Bacteria
All three bacteria species, B. cereus, B. subtilis, and B. thuringiensis, were
purchased from ATCC. All three bacteria cultures were inoculated in Luria Broth growth
media purchased from Sigma Aldrich.
Bacteria biofilm formations were created using two specific plates,
Polyvinylchloride (PVC) and MBEC plate. The polyvinylchloride plates used in the
Biofilm Assay I was purchased from Becton Dickinson and the second biofilm assay was
performed using an MBEC device purchased from MBEC.
Figure 7. MBEC Biofilm
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All bacteria testing were performed with fluorescent viability dyes and analyzed
with fluorescent Microscopy and Flow cytometry, donated by Christopher Sinigalliano
from the Environmental Research Center. The fluorescent viability dyes was Ethidium
homodimer- 1 and S o-9 that were initially purchased from molecular probes.
3.1.5 Equipment
Three specific types of equipment were used for liposome formation, these
included: the Buchii Rotovap colurn distillation, used for lipid film formation, the
Labonco Freeze Dry Chamber lyophilizer, used to remove excess solvent from the lipid
film, and the Mini extruder apparatus, used to create liposomes. The size distributions of
these liposomes were verified through SEM imaging analysis performed by the
Nanofabrication facility.
Antibody and Streptavidin synthesis verification testing were performed by two
specific techniques, Protein absorbance and BCA assay. The Tecan Genios was used to
determine protein concentration by measuring the absorbance of the antibody and
streptavidin intermediate samples at 260nm and 280nm wavelengths. The final product,
streptavidin-antibody complex, protein recovery was determined with the BCA assay
purchased from Pierce and analyzed with the Tecan Spectrophotometer.
All bacteria cultures were grown in a Shaking Incubator, and the bacteria culture
concentration was determined with the use of a Biorad 3000 Spectrophotometer. A
quantitative live/dead fluorescent assay was performed with the fresh bacteria culture and
analyzed by flow cytometry.
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3.2 METHODS
3.3 Liposomal Encapsulation
Specific Aim I of this project consisted of creating 100 nm liposomes
encapsulated with MgO-Cl2 nanoparticles.
3.3.1 Experimental preparation
3.3.1.1 Determining concentration of liposome encapsulant, MgO-C1 2
Before liposome formation, the maximum concentration of MgO-C1 2 nanoparticles
that could be circulated within the mini extruder had to be determined. Since the mini
extruder apparatus is a manually driven device, high concentrations of MgO-C1 2
nanoparticles result in high resistance and ruptured membranes. Therefore, one
experimental aim was to determine, the nominal concen ation of MgO-C1 2 that could be
circulated within the mini extruder apparatus, while still maintaining membrane integrity.
Therefore, various MgO-C1 2 concentrations were prepared by serial dilutions to
assist in determining the optimal concentration that could be circulated within the mini
extruder apparatus. First, five test tubes were labeled in numerical order, and were filled
with 1 ml of HEPES buffer. Secondly, a 5 mg/ml stock solution of MgO-C1 2 was created
and dispensed into test tube 1 and test tube 2. A 1:2 dilution was performed on the
remaining test tubes until the last test tube had a theoretical concentration of 0.185
mg/ml. Reference for theoretical concentration corresponding to each sample are shown
in Table 2.
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Test Concentration
tube no. (mg/mi)
2 2.5
3 1.25
4 0.75
5 0.37
6 0.185
Table 2. Dilutions of MgO-C1 2 in HEPES buffer
3.3.2 Testing the Dilutions of MgO-C 2 with Mini extruder
The mini extruder apparatus (Figure 8) was prepared for MgO-Cl2 serial dilution
testing, by placing two filter supports on each membrane holder, and a 100 nm
polycarbonate membrane sandwiched between both membranes holders, as shown on
Figure 8. Next, the joined membrane holders were set into the corresponding metal
holders and placed on a hotplate. The hotplate temperature was adjusted to achieve a
steady temperature of 62 C. Once achieved, each serial diluted sample was vortexed and
sonicated, until all the MgO-C 2 nanoparticles were suspended in the solvent creating a
homogeneous solution. Next, 1 ml of the homogeneous solution was extracted using an
extruder syringe and set on one side of the Mini extruder apparatus. Next, the second
extruder syringe was placed on opposite side of the extruder, as shown on Figure 9.
Then, the serial diluted sample was circulated through the membrane, alternating syringes
for a total of 10 times, while documenting all experimental observations.
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Each extrusion procedure performed on the serial diluted MgO-C1 2 samples were
examined for two experimental parameters; such as, resistance and product buildup on
the filter supports. These two parameters were documented for each sample, and the
experimental results were observed at the end of the overall experiments. The results
were carefully examined, and it was concluded that the maximum concentration of MgO-
C1 2 that could be circulated within the extruder was 0.37 mg/ml.
Figure 8. Mini extruder apparatus
Figure 9. Assembly of filters and membranes into extruder
3.3.3 Liposome Column Preparation
Liposomes purification was performed with Size Exclusion Chromatography
(SEC), specifically using Sephadex G-50. This type of sephadex was chosen for its bead
pore size (20-80 tm), and its ability to retain free-floating low molecular weight
compounds, and elute pure liposomes. These Sephadex G-50 columns were prepared by
swelling the sephadex beads in HEPES buffer, and then packing them into 5 ml syringes,
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creating sephadex mini columns. The exact buffer and bead swelling information used
followed the protocol where 1 gram of Sephadex G-50 required 9-11 ml of buffer to
swell the sephadex beads. So for our experiments, 44 ml of HEPES buffer and 4 g of
sephadex were placed in a 50 ml conical tube, and were allowed to swell for three hours
at room temperature. As the sephadex beads swelled, the glass wool packing agent was
soaked in HEPES buffer. Then, a small piece of soaked glass wool was packed tightly
inside a 5 ml plastic syringe.
Once the Sephadex had swelled, the sephadex conical tube was placed in a hot
water bath for several minutes to degas. Then, the warm sephadex was carefully poured
into the mini column until the bead height reached the 3.5 ml mark on the syringe. Next,
each mini column was carefully examined for the presence of air bubbles. Once no air
bubbles were visible, the Sephadex G-50 columns were ready for liposome purification.
3.3.4 Lipid Film formulations
The lipid composition for liposome formation was attained followed from previous
experiments from Creation of a novel, Magnetic Drug Delivery Complex, Danny
Gonzalez. Specifically for this thesis, one main lipid formulations were created. Then
two additional lipid formulations were created following the main formulation except
with cholesterol concentrations variation. These additional lipid formulations were
created to assist in determining if the actual concentration of cholesterol within the lipid
film had a direct affect in the release of the encapsulant agent, MgO-Cl2, in neutralizing
bacteria. The following formulations were:
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1. Biotin-DSPE-PEG2000, Phosphatidylcholine, Cholesterol (Main Formulation)
(1:9:5 Mole Ratio).
a. Biotin-DSPE-PEG2000, Phosphatidylcholine, Cholesterol,
(1:9:9.9 Mole Ratio)
b. Biotin DSPE-PEG2000, Phosphatidylcholine
(1:9 Mole Ratio)
An additional lipid formulation composed of a different Biotin linker was created
to determine if the Biotin linker composition had an affect in bacteria detection. The
formulation was the following:
2. Biotin-DSPE, DSPE-PEG2000, Phosphatidylcholine, Cholesterol
(1: .5,5,9).
3.3.5 Lipid Film
All the lipid films were created in chloroform pre-treated 50 ml air free round
bottom flasks. Two types of lipid film formulations were created, these included:
1. Biotin-Capped DSPE-PEG2000, Phosphatidylcholine, and Cholesterol
(7.5 mg, 46 mg, 13 mg)
2. Biotin-DSPE-PEG2000, Phosphatidylcholine, Cholesterol,
(7.5 mg, 46 mg, 26 mg)
3. Biotin DSPE-PEG2000, Phosphatidylcholine
(7.5 mg, 46 mg)
4. Biotin-DSPE, DSPE-PEG2000, Phosphatidylcholine, and Cholesterol
(5 mg, 2.5 mg, 34 mg, 9.7 mg)
The lipids were dispensed into a round bottom flask with 5 ml of Chloroform
solvent, immediately creating a homogenous solution. Next, the sample was placed on
the Buchi Rotovap with specific settings to assist in lipid film formation, which included:
Placing the round bottom flask at a 450 angle, to prevent lipid clumps from forming on
the bottom of the glassware. Adjusting the water circulator temperature to 14C and the
water bath to 380C. Set the rotational speed to 145 rpm under vacuum pressure, for
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approximately an hour, to promote a thin lipid film formation. Once a thin lipid film was
achieved, the lipid film was frozen in liquid nitrogen Lypholized overnight.
3.3.6 Rehydration of Lipid Film
The previously created freeze-dried lipid film was rehydrated with 7 ml of a 10%
trehalose 3 mM HEPES solution with 2 mg of MgO-C1 2. The rehydrated lipid film was
placed on the Buchi Rotovap and spun at 165 rpm with the water bath temperature set at
55C. As the lipid film was spun in suspension, the lipid film started to dissociate from
the flask walls and emulsifies in the trehalose solution. After an hour the solution
consisted of multilamellar vesicles (MLV), and was freeze-thawed five times under liquid
nitrogen, to maximize MgO-Cl 2 concentration retained within the aqueous cavity of the
liposome. Once this procedure was performed, the MLV solution was ready to be
extruded to created 100 nm large unilamellar vesicles (LUV).
3.3.7 Extrusion of Large Unilmellar liposomes
A series of mini extruder preparation procedures were performed for the liposome
rehydration process. The first step was to soak the filters and membranes in a 10%
Trehalose 3 nM HEPES buffer solution for several minutes. Next, two hydrated filter
supports were inserted on both membrane holders, and a hydrated filter membrane
sandwich between both membrane holders, shown in Figure 9. The apparatus was
assembled, and was placed on a hotplate, where the temperature was set to reach a steady
temperature of 62'C. Once the temperature was achieved, 1 ml of the previously freeze
thawed liposome sample was drawn using the extruder syringe, and placed on one side of
the mini extruder apparatus. Then, the second extruder syringe was placed on the
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opposite side of the mini extruder apparatus, as shown on Figure 9. The freeze-thawed
MLV sample was circulated within the extruder membrane by passage through
alternating syringes for a total of 10 times, creating 100 nm LUV. The LUV sample and
residual MLV sample were dispensed into independent glass storage vial, and were
stored at -20 C, until further use. The schematic diagram below shows liposome
formation from start to finish.
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Figure 10. Diagram of liposome formation
3.3.8 Purification of Biotin-Liposomes
Each freshly extruded sample contained both liposomes and freed floating non-
encapsulated MgO-C1 2. So to achieve a pure liposomes solution, the samples were
purified with Size Exclusion Chromatography (SEC).
3.3.8.1 Sephadex Centrifuge Purification
The second liposome purification procedure, involved dispensing the extruded
liposome sample into a Sephadex G-50 mini columns, and centrifuging the mini column
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with the sample to eliminate free-floating MgO-Cl 2 in solution. This purification method
was developed by Validimir Torchilin, and is widely accepted for achieving high
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recovered and non diluted liposome recovery
The liposome purification procedure was performed through a series of steps.
First, the previously created sephadex mini colurns were placed within a sterile 15 ml
conical tube, and loaded inside a swing rotor bucket centrifuge, spun for 3 minutes at
1000g. After centrifugation, the centrifuge was opened and the 15 ml conical tubes
containing the mini column with the excess buffer was discarded. Then, the mini-
columns were placed into a new sterile 15 ml conical tube, and 1 ml of liposome sarple
was dispensed into the corresponding almost dry sephadex mini column. The sephadex
columns were placed again in the centrifuge and spun for 10 minutes at 50g, and for 3
additional minutes at 1000g. The final eluted liposomes samples were recovered in the
conical tube, and were stored at -20*C for further analysis.
3.3.9 Liposome Verification via Scanning Electron Microscopy (SEM)
After liposome purification, the liposome samples were prepared for SEM analysis
in order to verify liposome presence and size. 20 [l of the liposome sample was
dispensed onto the carbon nanotube substrate, and was immediately immersed into liquid
nitrogen. Once the sample was frozen, it was immediately placed in the lypholizer
overnight to remove the excess moisture. The following day, SEM imaging analysis was
performed on the liposome sample. This preparation procedure was also performed on
the non-purified liposome sample.
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3.4 Immunoliposome -nanoparticle complex synthesis
The second aim consisted of creating a non-specie specific detection system
modified onto liposomes.
3.4.1 Synthesis of Streptavidin-Nanoparticle antibody Complex
The synthesis of the streptavidin-nanopa iles antibody complex consisted of a
fluorescently labeled Streptavidin-nanoparticles modified with a polyclonal antibody.
The specific polyclonal antibody utilized in this experiment targeted Bacillus anthracis
spores, but recognized the antigens on the surface of the bacteria Bacillus subtilis (ATCC
no. 9372) and Bacillus cereus (ATCC no. 11778). The actual antibody conjugation onto
the nanopa icles was performed by targeting the prime amine functional group. These
primary amine groups provided a target site for chemical synthesis to occur with the
assistance of a crosslinker. These crossli er allowed conjugation to occur, creating a 40
nm Streptavidin-nanoparticle-antibody complex. The final synthesis of the Streptavidin-
nanoparticle antibody complex was an easy procedure that utilizes the primary amine
groups of both the antibody and Streptavidin coated nanoparticle.
3.4.2 Streptavidin coated nanoparticle-MBS Synthesis
The Streptavidin-nanoparticles synthesis reaction occurred by using a specific
crosslinker, Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) that targets the
primary amine of the Streptavidin molecule. These Streptavidin nanoparticles were
received in a 1 ml bottle with a concentration of 0.5% w/w. Therefore, before any
experiments were performed, calculations were performed to determine the concentration
of nanop icles and crosslinker necessary to produce a high yield. From these
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calculations, it was determined that only 0.2 mg of nanoparticles wre ecessr for the
synthesis reaction and 2 mg of Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS),
First, the Streptavidin coated n op icles bottle was vortexed and 40 l of the
suspension was extracted and dispensed into a 15 ml conical tube with 4.3 ml of de-
ionized water and 0.7 ml of HEPES buffer. Then a 40:1 molar excess of MBS solution
was created, and 200 1 the solution was dispensed into the conical tube containing the
Streptavidin-n oparticles. The conical tube containing the nanoparticles and MBS was
placed in a water bath at room temperature and was gently stirred for an hour. This
reaction occurred immediately, but to ensure high crosslinking the sample was in ubated
for a longer time. The chemical synthesis reaction is sho below.
Figure 11. Streptavidin MBS Synthesis Reaction
3.4.3 Purification of Streptavidin-MBS complex
3.4.3.1 Preparation of Centriprep 30 Ultrafiltration device
While the Streptavidin-nanoparticles were reacting with MBS, the Centriprep 30
ultrafiltration device was prepared to purify the Streptavidin-nanoparticle-MBS sample.
These glycerin coated Centriprep 30 ultrafiltration devices were rinsed in HEPES buffer
to remove all traces of glycerin on the membranes.
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The Centriprep 30 ultrafiltration devices were dsassembled and 15 nl. of REP ES
buffer was added into the sample cavity, and then placed inside the centri u, ad spun
at 3000g for 15 minutes. After centrifugation, the buffer was decanted from the filtrate
cavity, and an additional 5 ml of buffer was added into the sample cavity. The Centriprep
30 ultrafil tation device was spun again for an additional 15 minutes at the same
conditions as previously set. After centrifugation, the filtrated s mple was decanted from
the filtrate collector, and centriprep was ready for the nanoparticle-mbs complex sample.
Figure 12. Centriprep Diagram. A. Centriprep 30 ultrafiltration device B. diagram
3.4.3.2 Purification fStreptavidin-MBS Complex
The Streptavidin-MBS complex was poured into the sample container of the
Centriprep 30 ultrafi tration device, and was loaded into the Biofuge Primo Rcentrifuge,
and spun at 3000g for 5 minutes. Then, the Centriprep cap was removed and the filtrate
collector sample was recovered in a 15 ml conical tube. The purified sample was re-
suspended in 2 l of HEPES buffer, and the filtrate collector was pushed up and dow
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against the buffer to released ato inner sur a e. Once most of the
nanopa iles were released, the purified Streptavidin-MBS intermediate sample was
transferred into a 15 ml conical tube and stored at 4 *C.
3.4 Antibody Thiolation
The polyclonal antibody sample (4 mo/mI) was taken out the refrigerator and
vortexed for 10 seconds. Next, 40 l of the antibody sample (0. mg) was extract d and
dispensed into a 15 ml conical tube, and diluted with 2 ml of HEPES buffer. Next, the 2-
iminothiolane (Traut s reagent), crosslinking agent was prepared to give a molar excess
of 40:1, with approximately 1 mg.
Then, the Traut's reagent was added to the 15 ml conical ube containing the
antibody, and the sample was placed in a water bath at room temperature and gently
stirred for an hour. This reaction occurred immediately, but to ensure high levels of
crosslinking, the reaction was extended 60 minutes. The chemical synthesis reaction is
sho below in Figure 13.
Figure 13. Antibody and Traut's reagent reaction
3.4.4.1 Antibody-Sh Sephadex column preparation
The Sephadex G-25 columns were prepared for antibody purification by swelling 5
g of Sephadex G-25 with 25 ml of HEPES buffer for three hours. While the sephadex
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beads were swelling, the mini columns were prepared. The glass wool packing agent was
placed in a beaker containing HEPES buffer for several minut - Then, a piece of
saturated glass wool was placed inside a plastic 5 ml syringe, and was packed tightly to
compact the glass wool within the mini colum n.
Next, the swelled sephadex was placed in a hot water bath for a minute to de-gas.
Once the sephadex was hot, it was gently poured into the packed syringes until the bead
height reached the 3 5 ml mark on the syringe Then, the mini col ns were set on th
benchtop, and were elecked for the prsence of air bubbles. If no air bubbles wre
present, the min- olumns were then ready for antibody purification.
3.4.4.2 Tliiolated Antibody Purification
After an hour of the ntibody and Traut's incubation, the sample was taken out of
the water bath and immediately poured on the top of the sephadex column. The sample
was allowed to elute under gravity for 5 minutes, and then 1 ml of HEPES buffer was
added to the sephadex column to assist in eluting the thiolated antibody. After several
minutes, the collected sample was immediately stored at 4 C until further testing.
3.4.4.3 Conjugation of Streptavidin-Antibody Complex
The Streptavidin-Antibody complex was created with the two intermediate
products previously purified. The antibody-Sh and Streptavidin-MBS intermediate
products were taken out the refrigerator and allowed to reach room temperature. Once at
ambient temperature, 150 1 of Streptavidin-MBS complex and 500 1 of the antibody-Sh
sample were extracted and dispensed into a 15 ml conical tube. The final sample was
shaken vigorously for 20 seconds, and then placed in a water bath at room temperature
42
and gently stirred overnight. The following day the samples were stored at -4"C. The
chemical synthesis reaction is shown below, in Figure 14.
Figure 14. Final Product Reaction
3.4.5 Verification Testing
3.4.5.1 Protein Recovery Tecan Spectrophotometer
All quantitative protein recoveries for both intermediate synthesis reaction wer
determined by measuring the absorbance values of the samples at 280nm and 260nm. By
implementing these absorbance values into the formula below, an estimate of the protein
recovery was determined.
Concentration (mg/ml) = (1.55 x A280) - 0.76 x A260)40
First, all the intermediate samples were allowed to thaw at room temperature.
Then, 25 [d of each antibody sample were dispensed into assigned positions on a sterile
96-well plate with 200 of HEPES buffer added into each well. Lastly, the final
column of the plate was filled with 225 pl of HEPES buffer as a control. The
experimental design is shown on the plate diagram below (Figure 15).
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Figure 15. Recovered Antibody Sample Plate diagram
The second 96-well plate was prepared for the intermediate products of
Streptavidin-mbs samples, following the same procedure as the antibody-Sh samples. 25
1 of Streptavidin-mbs sample were dispensed into assigned well within a specific
column. Then, 200 l of HEPES buffer was added to each well containing Streptavidin-
mbs product, and finally 225 1 of buffer was dispensed to the last colu
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Figure 16. Recovered Streptavidin Sample Plate diagram
The antibody-Sh sample well plate was loaded into the plate stand within the
Tecan Spectrophotometer and the sample was read at 280nm and 260nm The sample
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procedure performed for the antibody-Sh sample was performed for the Streptavidin-bs
samples. A total of two reading were performed for each plate at t o independent
wavelengths. All readings were recorded in excel for fu her an ysi.
3.4.5.2 BCA Assay
The BSA assay was first prepared by creating a working reagent that consisted of
two reagents, A and B creating a 50:1 solution. The working reagent was vortexed
vigorously for several seconds, and then placed on the benchtop for further experimen ts.
Next, Bovine Serum Albumin (BSA) standards were prepared by performing a series of
dilutions. First, a 2 mg/ml BSA capsule was broken and carefully transferred to an
eppendorf tube. A set of dilutions were prepared by using the stock BSA and HEPES
bu ffer, as shown in the Table below.
Vial Volume of Dilutent (p1) Volume ot BSA (p ) | Final Concentration (p g/m)
A 0 300 2000
B 125 375 1500
C 325 325 1000
D 175 75 of vialB 750
E 325 325 of vial C 500
F 325 325 of vialE 250
G 325 325 of vial F 125
H 400 100 of vialG 25
I 400 0 0
Table 3. BCA Standard Diagram
Once all the dilutions were performed for the standard assay, a sterile 96-well plate
was obtained and each column was assigned to each sample dilution. Next 200 1 of the
working reagent was dispensed into every well on the 96-well plate, and 25 xl of the
freshly prepared sample was dispensed to the corresponding well, as shown below. The
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last column on the plate was filled with 225 l of HEPES buffer. Finally, the well plate
was placed in a 370 C incubator for 2 hours.
H Hepe Hepe Hepe
Figure 17. BCA Standard plate diagram
After the well plate had incubated for approximately 2 hours, it was tken out the
incubator and allowed to cool at room temperature. Once cool, the saple well plate was
loaded into the spectrophotometer and the sample was read at 595n. The readings
obtained were recorded were graphed in excel, and an equation of a line was obtained
with an R2 value greater than 0.85. This equation of the line was used to determine
protein concentration.
The final streptavidin-antibody complex samples were taken out the refrigerator.
While the samples reached room temperature, 200 1 of the freshly created working
reagent was dispensed into every well in the 96-well plate, and 25 [l of each streptavidin-
antibody complex sample were dispensed into the assigned column. The well plate was
then placed in a 37'C incubator for two hours for the reaction to occur. After incubation
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the sample was loaded into the spectroplhotom eter and was rea d at 595nm.i Th value S
obtained were recorded in Excel for frher analysis.
3.4.6 Immunoliposome-nanoparticle Complex Conjugation
A 1:1 ratio of the previously created immunoliposores and st'eptavidin-an tibody
complexes was prepared in a 15 ml conical tube. The reaction attaclrent occurred
immediately, but reaction tim was increased to 30 minutes to insure conjugation After
this time period, the samples were stored in at -20*C until further testing. he schematic
diagram of the final complex is shown below (Figure 18).
Figure 18. Immunoliposome-nanoparticle Complex
3.5 Live/Dead Bacteria Verification Testing
The third aim involved conducting feasibility studies on the newly created
immunoliposome-nanoparticle complexes and bacteria to determine the time factor
involved in detecting and neutralizing bacteria pathogens.
3.5.1 Bacteria
Three bacteria strains were analyzed, which were: Bacillus cereus, Bacillus,
subtilis, and Bacillus, thuringiensis.
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3. .2 Badtera Preparat on
3.5.2.1 Media Preparation
Fresh Luria Broth (LB) bacteria media was prepared through a series of steps.
First, 1000 ml of distilled water was poured into a 2000 ml Erlenneyer flask w ith 20 g of
LB dry granules. Second, a magnetic rod was gently placed into the Erlenmeyer flask and
set onto a stirring plate. Third, the stirring plate setting was set to stir on high until a
homogenous solution was created within ten minutes.
After the media had been prepared, it was poured into three 500 ml glass bottles,
and placed into an autoclae for sterilization. After approximately an hour, the media
was taken out of the autoclave, and the bottles were placed on the bench top until
required for bacteria growth.
3.5.2.2 Agar Plate Preparation
Agar has been a commonly used media to inoculate a range of bacteria species
from both gram positive to gram-negative bacteria. These plates were prepared for
experimental drug bacteria interaction testing.
Agar was prepared by a series of steps. First, 500 ml of de-ionized water was
dispensed into a 1 L Erlenmeyer flask with 20 g of Agar. Second, the flask was placed
on a heating/stirring plate and a large magnetic rod was gently placed into the flask and
covered. Third, the flask was stirred and heated on low for several minutes until the
entire agar granules had dissolved. Then the agar solution was immediately placed in an
autoclave sterilizer for an hour.
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After the agar was cooled, it was poured halfway in each dish for a total of 20
Petri dishes. These dishes were allowed to cool at room temperature, until the agar had
completely gelled. After gelation, the agar plates were stored in the refrigerator for
further analysis.
3 r
Figure 19. Agar Plate
3.5.3 Bacteria Inoculation
A small sample of the Bacillus cereus freezer vial was dispensed into a sterile 50
ml conical tube, with 5 ml of freshly prepared LB media. Next, the bacteria conical tube
was placed within a shaking 37 C incubator overnight for bacteria growth.
3.5.3.1 Bacteria Concentration Assay
Fresh overnight bacteria culture was dispensed into a 1 ml plastic cuvette and was
set-aside on a bench top. Then, a 1 ml of LB media used in the same bacteria culture was
dispensed into a plastic cuvette, and loaded into the spectrophotometer and read at 600nm
to blank the machine. Next, the sample plastic cuvette was loaded into the
spectrophotometer, and an immediate absorbance value and concentration of the bacteria
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sample in cells/ml was obtained. From the obtaind con entration a dilution fa t r for
each experiment was determined for frter exp riments.
3.5.4 Bacteria and MgO-Cl2 Interaction Control Testing
Three distinct assays were used to test the e aization properties of MgO-C1 2
against bacteria. The first csay onsisted of incubatin btr with various MgO-C2
drug concentrations. The second assay known as halo test, incubated batera witl
Mo-Cl 2 loaded in the middle of the Petri dish. The t rd assay consisted of bacteria
bioflms treated with various MgO-C1 2 concentrations. All these assays were used to
determine the efficacious concentration of MgO-Cl2 required to neutralize bac~ra.
3.5.4.1 Bacteria incubati i with MgO-C1 2
Freshly grown, Bacillus cereus, bacteria sample in assumed exponential gro h
phase were examined by following the bacteria concentration assay to dete-rine bacteria
cell concentration in suspension. Once the concentration was obtained, a series of 1:10
dilutions were performed til the theoretical bacteria concentration was 105 cells/mi.
Next, five sterile conical tubes were labeled with the corresponding specific drug
concentration, and filled with fresh room temperature 50 ml of PBS Buffer. Then, the
various concentration of the neutralization agent (MgO-C 2) were added into a specific
labeled test tube, refer to Table 4.
Once the MgO-C 2 concentrations were added into each corresponding conical
tube, the samples were sonicated vigorously for several minutes, until a homogenous
solution was created. Then, 500 l of the fresh Bacillus cereus culture (cell/ml 05) was
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dispensed into each conical tube and vortexed for several second before bein placed in a
shaking 37*C incubator overnight.
Vial Dru we ighed F m) inal Concentration (mg/mI)
A 50 1
B 25 0®5
C 12.5 025
D 6.25 0$125
E 3.125 0.0625
F 0 0
Table 4. Prepared MgO-Cl2 Concentrations
Twenty-four hours after bacteria drug incubation, 500 'd of each sample were
dispensed into the corresponding agar plate. The bacteria agar plates were tilted until the
bacteria suspension completely covered the surface of the plate. Then each plate was
placed inside a 37*C incubator for 24 hours, and the plates were examined during the 24
hours interval for bacteria growth.
After 24 hours, each plate was examined for bacteria colony formation, and each
colony present was counted in specific plate regions. The overall bactericidal efficiency
of MgO-C1 2 was examined visibly. To future examine the bactericidal property of MgO-
C1 2, an equation was created to determine the overall bactericidal property of MgO-C1 2.
The following equation shown below was used to determine bactericidal efficacy'.
Bactericidal efficacy (%)= Alive number in control- alive number in experimental group x 100
Alive number in control
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3.5.4.2 Halo Test
Fresh bact ria cultures, ceres B. sbtili and B. thiniensis, were grown
overnight, and analyzed following the concentration assay to obtain a bacterial cell
concentration (cell/ml). Onc the concentration of ea h s mple was obtai ed e h
bacterium sample was diluted wit a 1:10 factor, until a theoretical concentration of 105
was obtained. Then, 500 1 of each diluted bacterium samples was dispensed into agar
plates, and incubated t 37C for 2 hours
hile the bactena wre proliferating, MgO-Cl2 d ug slurries were priared with 3
mg of MgO-C2 in 200 1 of HEPES buffer. After two hours of bacteria incubation, the
plates ver taken out of the incubator, and a strile 50 ml eonical tube was pressed ently
in th middle of cah plate, leavin an indentation. Then, the drug slurry was carefully
poured into the indented region and returned to the incubator, where th samples were
allowed to incubate overnight. The following day, the plates were examined for bacteria
colonies formation in the indented drug region.
3.5.4.3 Biofim Assay I
Bacteria strains were grown overnight in LB media, and analyzed the following day
with the concentration assay to determine the bacteria concentration in cells/ml. Once the
concentration was obtained, the samples were diluted in LB media with a ratio of 1:100.
Then, 100 pil of the diluted bacteria samples were plated into 96-well PVC plates, and
were placed in a microbiological incubator at 37C for approximately 10 hours.
The following day, the freshly created biofilms samples were treated with a variety
of MgO-Cl 2 concentrations. Each biofilm plate was treated with 100 [d of each drug vial
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listed below, and were placed in an incubator overnght. Drug killing ect was
determined by a plate-stre king assay that submer ed a lop into random wells from each
column, scraping the bottom of the biofilm, andr s specific area on an agar plate.
Note, that each column was specific for a drug concentration, and was repeated for each
PVC plate, until all the strains had been tested. Then, the agar pbates were placed within
an incubator for 48 hours. After two days. the plates were cx mined for bactena grow h,
and each colony present on each plate was documented. The presence of colonies was
used as positive indicator, if the varying th cone ntratin of Mg0-Cl had affected
bacteria growth.
Bacteria Concentration of Mg0ECl
B. subids
___________ 0 .5mig!
B. thu igen i 1 mg/ mi 0.mgm 0 2 /ni I r 0.2m/ml
Table 5. Biofilm MgO-C 2 Testing
3.5.4.4 Biofilm Assay II
The MBEC assay was the second biofilm assay performed with bacteria, B.
cereus, B: subtilis, and B. thuringiensis. Theses bacteria samples were grown overnight,
and were analyzed by following the bacteria concentration assay. Next, the bacteria
samples were diluted following a standard protocol, if 3.0 X 108 was the initial
concentration obtained, then a 1/30 dilution would be performed to obtain inoculums of
10 7 cells/ml.
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Then, 150 [d of the each diluted specie specific bacteria sample were plated onto
a 9 6-well EC plate, and were positioned within a gyrating incubator, set to 150 rpm
and 350C overnight
The followiNg day, rin ing p1t were prepred by dispensin 00 l of sterile
PBS in every well. Next, the Ihlen pltes were prepared by dispensing 00 l of
various MgO-C1 2 into assigned columns in the 96-well plate, as shown below.
Collmn Assiglcut w 1 U M 2OL n mI
12 & 11 0.5
10&9 0.35
0125
5 0.0625
Table 6. MgO-C 2 Plate layout for Biotlm Testing
The bacteria MBEC plates were taken out the incubator and placed in a sterile
hood, where the MBEC lid pegs were transferred into the rinse plate for approximately
one minute. Then the MBEC pegs were transferred into the MgO-C1 2 challenge plate, and
placed in the incubator for 24 hours.
On day three, the treatment plates were taken out the incubator and again
positioned in a sterile hood. While the rinse and recovery plates were prepared, the
MBEC biofilm lid from the challenge plate was transferred into the rinse plate with
sterile PBS, for approximately 1 minute. Next, CAMHB media was poured into a Petri
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dish where 200 [d were extracted and dispensed into the wells in the plate. After the pegs
were rinsed, the MBEC peg lid was transferred to the CAMHB recovery plate where the
plate was sonicated for 5 minutes to release biofilms from the pegs. Lastly, the plates
were set in the incubator for 24 hours to initiate bacteria growth.
On day four, the plates were taken out the incubator and were examined for
bacteria colonies both visually and with a spectrophotometer. The data obtained was
statistically analyzed to determine at what concentration of MgO-C1 2 inhibited bacteria
growth.
3.5.4.5 Fluorescent Microscopy of interaction between Bacteria and MgO-C 2
Before initial testing were performed, the fluorescent dyes, Ethidium homodimer-
1 and Syto-9 were calibrated for microscopy testing. A 1 [l of the stock Ethidium
homodimer-1 sample was diluted in 99 1 of HEPES buffer, creating a 1:100 dilution.
Next, 1 [d of the stock, Syto-9 dye was diluted in 999 1 HEPES buffer, creating a 1:1000
dilution. Then, two sample concentrations of MgO-C 2 samples were prepared in HEPES
buffer with a 24 mg/mI and 2mg/mi. Once all the MgO-Cl 2 preparation was finished
fresh, B. cereus, bacteria was obtained, and the concentration was determined.
Next, the dyes previously prepared were thawed and allowed to reach room
temperature. Once the dyes had reached desirable temperature, the samples were
prepared for testing analysis. Sample aliquots of the each MgO-C2 samples were
dispensed into the corresponding microscope slide with B. cereus and fluorescent dyes.
Next, the samples were analyzed with the 488nm blue laser on fluorescent microscope.
Live images were captured from each sample to view the interaction of
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Immunoliposome-nanoparticle complex sample with bacteria and fluorescent dyes. For
the purpose of this procedure sample aliquots of the original samples were viewed der
the fluorescent microscope at three time intervals time=O, time=15 and time=1 . The
samples volumes used in each test are listed below:
mple Formulation*
2 mg/mI MgO-Cl 2  2 [d of sample + 2 1 B. cereus
24 mg/mil MgO-C 2  2 1 of sample + 2 j B. cereus
Table 7. Fluorescent Microscopy testing with MgO-C1 2 and B. cereus
** All formulations consisted of 2 1 Ethidium homodimer-1 and 2 d of Syto-9
Each formulation was observed at different magnifications and the samples were
visualized using the Blue laser for fluorescent excitation
3.5.5 Bacteria testing with Immunoliposome-nanoparticle complex
3.5.5.1 Fluorescent Microscopy of interaction between Bacteria and
Immunoliposome-nanoparticle complex
All the samples were prepared for fluorescent microscopy by following the same
protocol previous used for MgO-Cl 2 testing. All the samples were prepared directly on
the microscope slide were the Immunoliposome-antibody complex samples, bacteria and
fluorescent dyes were analyzed immediately at different time intervals. The samples
volumes used in each test are listed below:
Additional fluorescent microscopy images were captured with another instrument,
and similar studies were performed with this microscope to capture images of the
56
interaction of B. cereus with liposomes. A sample slide of a 20 1 (B. cereus and
liposome 12) suspension with a 1:1 ratio was dispensed onto a microscope slides. Images
of the liposome and B. cereus interaction were captured at three intervals a time=O,
time=15 and time=l hour
Sample Formulation**
13-5 Imunoliposome-complex 2 l of sample + 2 1 of B. cereus
14-7 Immunoliposome-complex 2 1 of sample + 2 1l of B. cereus
14 Immunoliposome 2 1 of sample +2 1 of B. cereus
17 Immunoliposome 2 l of sample + 2 pl of B. cereus
Table 8. Fluorescent Microscopy testing with samples and B. cereus
Data acquisition of Bacteria and Immunoliposome interaction using Flow
Cytometry
Flow cytometry was used to determine the effectiveness of the newly synthesized
Immunoliposome-nanoparticle complex formulations in detecting and neutralizing the
bacteria samples. The bacteria samples concentration of 5.0 x 108 were prepared for flow
cytome . From this bacteria culture, 200 l was extracted and dispensed into a conical
tube containing 5 ml of LB Broth (1:25). The new bacteria conical tube was set aside, as
the Immunoliposome-nanoparticle complexes reached room temperature.
Next, the samples were prepared for flow cytometry testing with the following ratio:
25 1 bacteria sample + 200 1 of I unoliposome-nanoparticle complex + 25 1
Ethidium homodimer-1 (1:100 dilution). Once the samples were prepared, each sample
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Ethidium homodimer-1 (1:100 dilution). Once the samples were prepared, each sample
was immediately analyzed by flow cytometry to determine bacteria detection and
neutralization.
Bacteria detection was achieved by using the 488nm laser of the flow cytometer, and
triggering the yellow fluorescence of the nanoparticle within the Immunoliposome-
nanoparticle complex. The neutralization efficiency of the Immunoliposome-
n oparticle complex formulations was determined by the presence of the membrane
impermeable red fluorescent dye, Ethidium homodimer-1. Both the detection and the
neutralization of each sample were analyzed at two intervals, time=0 and at time=2 hours.
All the data obtained from flow cytometry were analyzed for live/dead bacteria cell
viability and for s ple interaction with the bacteria.
4.0 RESULTS
4.1 Liposome Formulation
4.1.1 MgO-C1 2 Drug concentration
An MgO-C1 2 serial dilution experimental design was created to determine the
maximum concentration of nanoparticles that could be circulated through the mini
extruder apparatus. All the serial dilution samples were tested under similar
environmental conditions used in liposome formation. The concentrations created are
shown in the Table below.
These serial dilutions samples were created by first starting with a high
concentration of 5 mg/ml of MgO-C1 2 nanoparticles, and diluting the sample by two
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folds, resulting in series of samples with high to low MgO-C1 2 concentrations. A total of
6 samples were created with a theoretical concentration range from 5 mg/ml to 0.185
mg/ml.
Sample no. Concentration (mg/ml)
1 5
2 2.5
3 1.25
4 0.75
5 0.37
6 0.185
Table 9. MgO-C 2 prepared Concentrations
The main focus of this experiment was to answer three main questions. 1. How
much resistance occurred when MgO-Cl 2 nanoparticles were circulated within the mini
extruder Apparatus. 2. Could the sample be circulated within the mini extruder apparatus
by alternating syringes for a total of 10 times? 3. Was nanoparticles buildup present on
the filter membrane after extrusion?
Favorable results were to obtain the highest concentration of MgO-C1 2
nanoparticles that would provide low resistance, capable of being circulated for a total of
10 times, and with no visible buildup on the filter membranes. A sample set of various
MgO-C1 2 concentrations were prepared extruded following the same protocol liposomne
procedure. All the experimentations were performed with each diluted sample listed
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above. The results obtained from each MgO-Cl2 sample and experimental results
obtained are shown below in Table 10.
Sample No. Concentration (mg/ml) Resistance Nanoparticle buildup
1 5Extremely High High White cake buildup
2 2.5 Extremely High High White cake buildup
3 1.25 High Resistance Slight cake buildup
4 0.75 Slight Resistance No buildup
*5 0.37 Normal Resistance No buildup
6 0.185 No Resistance No buildup
Table 10. MgO-Cl2 testing with Mini extruder Apparatus
* Optimal Concentration for liposome formulation
4.2 Lipid formulation
Two main lipid film formulations were created to understand the interaction of the
liposome mechanism in neutralizing and detecting the bacteria. These lipid formulations
were divided into two main categories as shown below:
A. Formulation One
a. 7.5mg (biotin capped DSPE-PEG2000), 46 mg PC, and 13 mg Cholesterol
b. 7.5mg (biotin capped DSPE-PEG2000), 46 mg PC, and 26 mg Cholesterol
c. 7.5mg (biotin capped DSPE-PEG2000), 46 mg PC
B. Formulation Two
d. 5 mg Biotin-DSPE, 2.5 DSPE-PEG2000, 34mg PC, 9.7 mg Cholesterol
A total of 12 films were created for testing, subdivided into four types of
formulation. These four formulations were developed from a two main formulations that
were altered in lipid concentration, resulting in four final formulations. For testing
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purposes each sample was designated a numerical log number corresponding to the
formulation category. A detail list of each type of formulation and each sample number
are shown in the Table below.
Sample No. Formulation
12 d
13 a
14 a
15 a
16 a
17 d
*18 a
*19 d
20 b
21 d
22 b
23 c
Table 11. Liposome samples with corresponding forrulation
The experimental steps in creating a lipid film formation are shown below. The step
consists of dissolving lipids in solvent and evaporating the solvent creating a lipid film.
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Figure 20. Lipid Film Steps A. Lipid in chloroform solvent B. Evaporating chloroform
C. final lipid film
4.3 Liposome
All the lipid films were re-hydrated in HEPES buffer with 0.35 mg/ml of MgO-C1 2
except for control samples 18 and 19. All these re-hydrated lipid films were freeze-
thawed five times under liquid nitrogen, and were circulated for a total of 10 times within
the Mini extruder apparatus, heated at 62 C. After extrusion, sample appearance changed
from an opaque white solution to a lucid solution, as shown in Figure 21. Note, the
sample opacity diminishes when LUV liposomes were created.
Non-liposome Lip osome Sample
Figure 21. Liposomes of lipid film 16
4.3.1 Liposome Purification verification
Scanning Electron Microscopy (SEM) examined the Liposome samples before
and after liposome purification via sephadex centrifugation. The SEM analysis was used
to obtain a positive verification of the presence and size of the liposomes before and after
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purification. These liposomes samples were fixed onto modified carbon nanotubes
substrates, and were examined to determine if the objectives were met. An SEM image
was captured from each sample before and after sephadex centrifugation. The results
obtained are shown below, note, both pictures show the circular shaped beads that are a
positive identification for the presence of liposomes within the sample collection.
k w
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Figure 22. Liposome SEM Imaging. A. Overview of liposome sample B. Close-up of
liposome sample
The purified liposome samples were analyzed by SEM, and the images obtained
are shown below, note, observed liposomes have an approximate 300 nm diameter size.
Figure 23. Purified liposome SEM
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4.4 Streptavidin-nanoparticle antibody complex Synthesis
4.4.1 Synthesis reaction of Antibody and Streptavidin
One main synthesis formulation was used to create eight samples of each
Streptavidin-mbs and tibody-Sh complexes. Each sample was purified by two
independent methods. The Streptavidin-mbs complex was purified via ultrafiltration, and
the antibody-Sh recovery was purified via Sephadex G-25.
4.4.1.1 Antibody and Streptavidin Yield
The Tecan spectrophotometer was used to determine the total protein yield for the
thiolated antibody and Streptavidin-Mbs complex synthesis's. Quantitative protein
recovery was determined by observing the sample absorbance at two specific
wavelengths, 260nm and 280nm. The protein recovery equation was implemented in
each sample, and the results obtained are shown below.
Figure 24. BCA Standard
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The BCA assay was performed on the streptavidin-nanoparticle antibody complex
samples, and the data obtained was standardized and analyzed using a one-way ANOVA.
A statistical model was created to determine if the streptavidin-antibody complex sample
created from the same formulation was statistically significant. The empirical model for
protein recovery was as follows:
Y= [+ Si+sj
Where 5= to the streptavidin-nanoparticle complex
The statistical results of the One-Way ANOVA produced a p-value of 0.000 for the
samples; this implies that these samples are significantly different. Also, the data were
normally distributed after natural log transformation.
4.5 MgO-C1 2 Testing
4.5.1 MgO-C1 2 Testing with Silver Nitrate
The MgO-Cl2 samples obtained from Nanomat Inc. were examined for the
presence of Chloride, C12, A series of samples were prepared in two types of buffers,
HEPES and de-ionized water. Next, several drops of 0.1 M silver nitrate were dispensed
into each prepared sample. The samples were examined after several minutes to
determine if a color change had occurred. Any physical change in solution was
documented before and after the addition of silver nitrate.
After 10 minutes the final sarple appearance was documented. The detailed
table was created to show the effects of silver nitrate to each sample in buffer, refer to
Table 13.
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Sample Observation before Observation after
AgNO 3  AgNO 3
l2 in Clear solution Clear solution
Na i in DI Clear Solution Opaque whi Solution
MgO-CL2 HEPES w/o salt Clear Solution Milky white solution
-gOCl2 in DI Clear Solution Brown solution
DI Clear Solution Clear solution
HEPES w/o Salts Clear Solution ilky white solution
HEPES w/o Phenol Read Clear Solution Milky white solution
1% Triton X HEPES Clear Solution Milky White Solution
Table 12. Silver Nitrate Test Results
4.51A Spectrophotometer Scan of MgO-C 2
An absorbance specturn scan of MgO-Cl 2 nanoparticles was taken with the Cary
UV-Vis. The absorbance scan of MgO-Cl 2 was analyzed, and it showed the highest peak
at 259 nm with a corresponding absorbance of 0.4204.
1N
2il
9M
0 0
200 250 300 35040
Wavelength (nm)
Figure 25. MgO-Cl2 Absorbance Scan
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4.5.1.2 X-Ray Microanalysis
An additional chemical characterization of MgO-C 2 was performed via X-ray
Microanalysis to determine the chemical element composition of these nanoparticles.
When the samples were analyzed, the results attained indicated that these MgO-C1 2
nanoparticles contained a high weight percentage of Magnesium (Mg+) 42.22 and
Oxygen (0-2) 40.10 with a 4.12 weight percentage of Cl 2. These findings confirm that
these nanoparticles do contain C12, refer to Figure 26.
0 Xa
Figure 26. X-Ray microanalysis of MgO-C1 2 nanoparticles
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4.6 Live/Dead Bacteria Verification testing
4.6.1 Bacteria and MgO-C 2 Interaction Control Testing
4.6.1.1 Bacteria incubation with MgO-Cl2
The bacteria strain Bacillus cereus was tested with various concentrations of MgO-
Cl 2, such as: a) 1 mg/ml, b) 0.5 mg/ml c) 0.25 mg/ml d) 0.125 mg/ml e) 0.0625 mg/ml f)
0 mg/ml. When B. cereus samples were incubated with each MgO-Cl 2 concentration and
plated onto agar plates, bacteria growth occurred with the majority of the incubated
MgO-C 2 concentrations. The results obtained are shown in the Figure 27 note; samples
A and B had no bacteria growth, which corresponded to MgO-C 2 concentrations 1 mg/ml
and 0.5mg/ml.
A FF F
Control
E D
Figure 27. Bacteria Incubated with MgO-C1 2
A) 1 mg/ml B) 0.5 mg/ml C) 0.25 mg/ml D) 0.125 mg/ml E) 0.0625 mg/ml F) 0 mg/ml
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4.6.1.2 Halo Test
The Halo test was performed on three specific bacteria strains, B. cereus, B.
subtilis, and B. thuringiensis. These bacteria strains were grown and plated onto agar
plates with 3 mg of MgO-C1 2 slurry administered into the center of each plate. After 48
hours, the plates were examined in the halo region for bacteria growth. The results
obtained show that in a plated region with an initial high bacteria concentration, bacteria
growth occurred within the halo region containing the MgO-C1 2 slurry, refer to Figure 28.
A. B
A. B. cereus
B. B. subtilis
C. B. thuringiensis
Figure 28. Halo test with Bacteria samples
4.6.1.3 Biofilm Assay I
A biofilm assay was performed on three specific bacteria strains, B. cereus, B.
thuringiensis, and B. subtilis. A 1:100 dilution of each bacterium culture was performed
and then plated into the corresponding PVC plate. After 24 hrs of incubation, biofilm
formation occurred on the bottom of the well plate, and a variety of MgO-C1 2
concentrations were dispensed into the corresponding well columns.
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A. Bacillus subtilis
B. Bacillus thuringiensis
C. Bacillus cereus
C.
Figure 29. Bacteria Biofilm results using Biofilm assay I
The plates were incubated for 24 hours. Then, random column wells were
scraped and streaked on specific areas on an agar plate. Then the plates were observed
after 48 hours for bacteria growth, which occurred on every designated streaked area,
shown above.
4.6.1.4 Biofilm Assay II
The MBEC assay was the second Biofilm assay performed with bacteria cultures,
B. cereus, B. thuringiensis, and B. subtilis. All three strains were incubated in the MBEC
device to generate biofilms on the peg lids. Once the biofilms were formed, each plate
was treated with various MgO-C 2 concentrations for 24 hrs. Then, the peg lids were
rinsed and transferred to a plate containing media, where the plates were sonicated to
release the biofilms. The plates containing released biofilms were treated with MgO-C1 2
plates were incubated for 24 hrs, and were visibly examined for bacteria colonies
formation. All bacteria colonies were documented, and the results obtained are shown on
Table 13. Additional bacteria colonies, absorbance counts were taken for each recovery
biofilm plate by absorbance plate reading.
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Bacteria plate MgO-C 2 Cone.
# wells w/bacteria colonies
A B C D E
B. cereus 0 6 1 2 15
B. thuringiensis 1 11 3 3 14
B. subtilis 0 4 10 10 12
Table 13. MBEC bacteria results after incubated with MgO-C12
MgO-C1 2 concentrations corresponding to:
A) 0.5mg/mI B) 0.35 mg/ml C) 0.125 mg/mI D) 0.0625 mg/ml E) 0 mg/mi
The absorbance reading of each plate was statistically analyzed by a one-way
ANOVA. A statistical model was created to determine if the MgO-C 2 concentration
affected biofilm bacteria neutralization. The empirical model for bacteria neutralization
was as follows:
Where F= MgO-C 2 formulations
A p-value < 0.05 was obtained with respect to the bacteria colony presence after
treatment of MgO-C 2 concentrations in regards to biofilms. The low p value indicates
that the MgO-Cl 2 formulations within bacteria strains had adverse affects, thus were
significantly different. Lastly, a statistical model for the three bacteria strains were also
analyzed using an ANOVA test with two factors. The model for overall bacteria
interaction with MgO-Cl,2 are shown below.
Y= + F i + Bj+ Fi+
Where F= Formulations and B= Bacteria strains
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The p-value of the new model for the affects of MgO-C1 2 on three Bacillus strains
were analyzed and formulation, bacteria strains, and the interaction had a p-value less
than 0.05, which indicates that they were significantly different.
4.6.1.5 Fluorescent Microscopy of interaction between Bacteria and MgO-Cl2
The second sets of fluorescent images captured the effects of the bacteria sample,
B. cereus, incubated with a stock concentration of MgO-C1 2 (2 mg/ml). The fluorescent
dyes Syto-9 (Green) and Ethidium homodimer-1 (Red) were used to determine the
neutralization effects of MgO-C1 2, when introduced to the bacteria cultures.
The green fluorescent bacteria rods represented the live bacterium, and the red
fluorescent bacteria cells represented the dead bacteria cells. When the samples were
analyzed at time=0, the sample had both red and green rods present. Within the samples,
it was observed a large community of either red or green rods within a given sample.
These images were captured when bacteria and MgO-C 2 were initially interacted, shown
in Figure 30.
b
Figure 30. Fluorescent microscopy images of B. cereus and MgO-Cl 2 A. B. cereus with
2mg/ml of MgO-C1 2 at time=0 B. B. cereus with 2mg/ml of MgO-C1 2 at time=0
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4.7 Bacteria Testing with Immunoliposome nanoparticle Complex
4.7.1 Biofllm Assay II
The same MBEC assay previously performed with MgO-Cl2 was performed using
B. cereus and the liposomes samples. In this test, each liposome sample was dispensed
into specific wells in the MBEC device to treat bacteria bioflm. After 24 hrs, bacteria
growth was observed and documented refer to figure 31. Also, absorbance reading of the
plate were taken and then statistically examined.
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Figure 31. MBEC B. cereus biofilm results after incubated with Liposomes
The absorbance data obtained was statistically analyzed using a one-way ANOVA
test. A statistical model was created to determine if the liposomes samples had an affect
on neutralizing B. cereus. The empirical model used for bacteria neutralization was as
follows:
=+ L +j
Where L= different liposome samples
A p-value of 0.153 was obtained from the ANOVA test, which indicates that the
liposomes samples were not significantly different.
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4.7.2 Fluorescent Microscopy testing
Fluorescent microscopy captured the interaction of the bacteria with the
Immunoliposome-nanoparticle complex. The liposome and bacteria interaction is shown
on Figure 32(a) and (c), and the liposome antibody interaction is shown on Part b.
a. b. C.
Figure 32. Fluorescent Microscopy Images of liposome and B. cereus. a. B cereus b.
liposome 12 c. nanoparticle-antibody complex 5
The liposome sample and Bacillus cereus interaction were captured at three time
interval, refer to Figure 33. All these were captured using a Fluorescent microscope and
viewing the samples under three specific magnifications.
Figure 33. Fluorescent microscopy images of B. cereus and liposomes at time intervals a.
Liposome 12 with B. cereus at time=0 b. Liposome 12 with B. cereus at time=15 minutes
c. Liposome 12 with B. cereus at lhr.
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These samples were stained with DAPI and Ethidium homodimer-1 and images
were captured at time =30 and after 60 minutes, refer to Figure 34. In both staining after
a 30-minute interval live bacteria were still seen.
ab
Figure 34. Fluorescent microscopy images of B. subtilis with sample 13-5 a. B. subtilis
stained with DAPI interacting with Liposome complex 13-5 after 30 minutes b. B.
subtilis stained with Ethidium homodimer-1 interacting with Liposome complex 13-5
after 30 minutes stained
Additional images were captured after the B. subtilis were incubated for an hour
with the liposome-complex 13-5. When the images were analyzed, it showed a minimal
amount of DAPI live cells, and a high concentration of dead red bacteria cells.
a b
Figure 35 Fluorescent Micrographs of B. subtilis with Immunoliposome-nanoparticle
complex. a. B. subtilis stained with DAPI interacting with Liposome complex 13-5 after
an hour stained b. B. subtilis stained Ethidium homodimer-1 interacting with Liposome
complex 13-5 after an hour
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4.7.3 Data acquisition of Bacteria and Immunoliposome interaction using Flow
Cytometry
Flow cytometry was used to study the interaction of the bacteria samples with the
i unoliposomes-nanoparticle complexes. These interactions were studied by using the
(488 blue laser) of the flow cytometer, and by triggering the fluorescent property of
the nanoparticle (577 ) conjugated to the liposome complex to detect the bacteria,
shown in the FL2 gated region (580/30 ). The neutralization efficacy of the liposomes
was analyzed by using a live dead assay with specific cell viability dye, Ethidium
homodimer-1, activated in membrane-compromised cells shown in FL3 gated region
(630/30 ). The interaction of the novel complex with the bacteria sample resulted in a
shift to the bacteria control gated region (ethanol treated), a positive indication of the
neutralization efficacy of the liposomes.
The bacteria sample B. subtilis was interacted with the Immunoliposome-
nanoparticle complex number 13-5, and with two fluorescent dyes, Syto-9 and Ethidium
homodimer-1. The sample was analyzed at time=0, and the data outputs were obtained in
histograms (Figure 36). These histograms were gated at specific regions for accurate
interpretations.
The first gated region, R1, represents the dead bacteria ethanol neutralized
controlled region stained with Ethidium homodimer-1. The second gated region, R2,
represents the live bacteria sample stained with Syto-9. Furthermore, the gated region R3
and R4 correspond to the "live" and "dead" peaks, based upon percentage of staining by
Ethidium homodimer-1.
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Figure 36. B. subtilis immunoliposomes-nanoparticle complex 13-5 at time zero
As shown in Figure 36, a majority of the bacteria samples once interacted with the
Immunoliposome-nanoparticle complex were still alive.
Live- blue
Figure 37. B subtilis immunoliposomes-nanoparticle-complex after 2 hours
After two hours of the bacteria and Immunoliposome-nanoparticle complex
interaction, a shift in fluorescent occurred, a portion of the cells in the R3 (blue) gate
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shifted to the R4 (red) gate. An overlay of both histograms at different time intervals is
shown below.
Green- Complex 5 at t=0
Blue- Live B. subtilis 'S'
Red- 2 hours of treatment
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Figure 38. Bacillus subtilis interaction after treatment
A series of detection and neutralization assays were performed with B. cereus,
and the newly synthesized Immunoliposome-nanoparticle complexes. The
Immunoliposome-nanoparticles complexes were subdivided into categories
corresponding to the attached nanoparticle-complex sample; half of the liposomes were
conjugated with nanoparticle-antibody complex 10 and the second half with
nanoparticles-antibody complex 11. Each complex sample was interacted with live
bacteria and Ethidium homodimer-1. The samples were analyzed by flow cytometry at
two time intervals, time=0 and time= 2 hours, see Figure below.
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Figure 39. Overlap of complex 10 with B. cereus a. time=0 b. time= 2hrs
Bacteria detection was observed with various types of liposomes and with both
types of nanoparticle complexes. As shown in Figure 39, the greatest shift in fluorescent
occurred after two hours with samples, 14-10, 15-10, 16-10, which all belonged to
formulation (a), an indication of an increase of nanoparticles adhered to the bacteria.
However, sample 12-10, 17-10 from formulation (d) did not show an increase in
detection.
Also, it was examined that both samples 13-10 and 17-10 showed some
dissociation from the bacteria after two hours, a negative indicator. Nonetheless, all
liposome nanoparticle complex formulations interacted with bacteria resulted in an
immediate detection with some outliers.
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Figure 40. Overlap of complex 11 with B. cereus a. time=0 b. time=2 hrs
The liposome samples conjugated with the nanoparticle complex 11 were
interacted with B. cereus and analyzed at two time intervals, shown Figure 40. All the
Immunoliposome-nanoparticle complex samples interacted with B. cereus resulted in
bacteria detection indicated by the right tail in the histogram (figure 40.b). From these
tests, it indicates that all the lipid formulation had similar results in detection at time=0.
After 2 hours, detection slightly increased, represented by a broad histogram. Although,
the lipid film formulation (b) sample 22-11, showed bacteria nanoparticle dissociation
after 2 hr, apparent by a sharp histogram.
After the samples were analyzed for bacteria detection, they were further analyzed
for bacteria neutralization using a "dead" fluorescent dye, Ethidium homodimer-1. For
testing purposes, control regions were created for accurate interpretation of the
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experimental data, these control regions consisted of: B. cereus incubated with
0. 3 5mg/ml of MgO-C 2 for 6 hours, ethanol neutralized B. cereus, and the live region
(syto-9). All the samples were analyzed with fresh bacteria cultures in assumed
exponential growth phased were used to determine the liposome formulations efficacy,
refer to Figure 41.
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Figure 41. Immunoliposome Formulation (a) interacted with B. cereus a. time=0 b.
time=2 hrs
The lipid film formulations were grouped together in one histogram to
demonstrate the effectiveness of the liposomes in neutralizing B. cereus. The lipid film
Formulation (a) individual histograms were grouped together and analyzed to determine
the effectiveness of the liposome in neutralizing bacteria. As shown in Figure 41, the five
independent liposome samples acquired different bacteria neutralization rates.
The greatest neutralization effect at time=0 was achieved with sample 16-10, and
when analyzed after 2 hours the histogram peak was located in the ethanol neutralized
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region. Thus indicating that the greatest killing effect was achieved by sample 16-10.
Also, the samples 14-10 and 15-10 displayed similar neutralization characteristics at both
time intervals, with the highest effect after 2 hours. Additionally, the lipid film 13-10 and
18-11 both had similar histogram peaks throughout the time interval, while having a large
percentage after two hours in the live-gated region.
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Figure 42. Immunoliposome Formulation (b) interacted with B. cereus a. time=0 b.
time=2 hours.
The second Formulation (b) was analyzed to determine the effectiveness of lipid
film in neutralizing bacteria. In this study the samples 20-11 and 22-11 were analyzed,
and both the results were analyzed showed wide variability in neutralizing bacteria.
Hence, the greatest killing effect at time=0 was achieved with the lipid film 20-11, which
increased eradication when incubation time was increased. Note, the greatest histogram
peak of sample 20-11 occurred beyond the ethanol gated control region (Figure 42).
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Figure 43. Immunoliposome Formulation (c) interacted with B. cereus at time=0 and
time=2 hrs
The third Formulation (c) had similar effects at time=0 and after 2 hours. The
broad histogram indicated that the eradication effect was equally distributed within the
neutralized MgO-C1 2 gated region. Thus indicating that the maximum neutralizing effect
occurred at the initial bacteria and Immunoliposome-nanoparticle complex interaction.
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Figure 44. Immunoliposome Formulation (d) interacted with B. cereus a. time=0 b.
time=2 hrs
The last lipid film Formulation (d) histograms when analyzed at both time intervals,
showed similar bacteria killing effects. When the sample was examined at time=0, all the
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histogram peaks were in the well designated live gated region with a right tail in the
neutralized region. As the time increases, Sample 12-10, 18-11, 17-10, all showed
similar results with histograms in the live region. Nonetheless, Sample 21-11 showed a
greater shift towards the dead ethanol gated region, after 2 hours of bacteria sample
incubation. So of these samples, 21-11 was more efficient in neutralizing bacteria.
5.0 DISCUSSION
The task to develop a new method that can effectively detect and neutralize bacterial
biohazards in a short interval is very challenging. In this project, the novel detection and
neutralization assay was achieved by using liposomes encapsulated with MgO-Cl2
(Neutralization Agent) conjugated with a modified streptavidin-nanoparticle antibody
complex (Detection Complex). The overall effectiveness of this novel assay was further
analyzed with bacteria in vitro models.
The objective of specific aim I was to synthesize 100 nm liposomes encapsulated
with a neutralization agent, MgO-C1 2 . So prior to liposome formulation, the optimal
MgO-C1 2 concentration capable of being circulated within the mini extruder apparatus
was determined by vigorous serial dilution testing. From the testing results, it concluded
that the maximum MgO-Cl 2 concentration capable of being encapsulated within
liposomes using the mini extruder apparatus was 2.5 mg/ml.
Once the optimal MgO-Cl2 concentration was determined, the liposome formulation
protocols were developed taking in consideration the two main project objectives being:
1. Rapid bacteria detection 2.Rapid bacterial neutralization. With these two objectives in
mind, two main lipid formulations were created to assist in determining the optimal
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liposome formulation for rapid bacteria detection. These two main lipid formulations
differed by the type of biotin lipid attachment added to the main formulation. The
importance of the biotin component is crucial for the attachment site of the detection
portion (streptavidin coated nanoparticle antibody complex) to adhere to the bacteria. The
structure formation of the attachment of Streptavidin and Biotin formation can provide
either favorable or unfavorable structure formation that can either promote or dissociate
attachment to the bacteria. With this reasoning, the biotin additive in both formulations
can help determine the nominal biotin compound necessary to enhance bacteria detection.
Additional liposome formulations were created to gain an understanding exactly how
lipids components such as Cholesterol play an essential role in the releasal of the
encapsulated material in neutralizing bacteria. So two additional formulations were
created with varying concentrations of cholesterol in order to establish the successful
formation in both detecting and neutralizing bacteria pathogens.
The first specific aim called to verify the presence of liposomes in solution. This was
accomplished by SEM analysis , the positive visual identification of the presence and size
of these liposomes was confirmed. One of the main objectives of this thesis was to
produce a solution containing 100 nm liposomes, but from the images captured the
smallest liposome size visibly analyzed had a diameter size ranging from 177 nm to 212
nm. The SEM analysis indicates that a widespread liposome size distribution is apparent
within the sample specimen.
The Liposome diameter size can be altered from the initial liposome extrusion to the
final purification procedure. So creating an exact 100 nm liposome solution is nearly
impossible given the current membrane porosity of 100 nm. So in order to achieve a
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liposome solution containing a wide spread size distribution of 100 nm, a smaller pore
less than a 100 nm would be required.
The projects second specific aim addressed the synthesis and recovery (yield) of both
the antibody-Sh and the streptavidin-nanoparticle complex. The absorbance reading of
each recovered sample showed a widespread viability with an antibody concentration
ranging from 0.085 mg/ml to 0.288 mg/ml, achieved from sample 8 and 4. These
samples were all created following the same protocol formulation. The Streptavidin-
nanoparticle-mbs complex samples recovered showed a range of sample recovery from a
low 0.267 mg/ml to a high 0.918 mg/ml, achieved from sample 9 and 5. The widespread
variability demonstrated that each individual sample recovered achieved similar results
from the final sample, calculated by the BCA assay. So manual generation of streptavidin
and antibody extraction with the initial synthesis reaction could account for the protein
recovery (yield) variability.
The third specific aim of this project consisted of general live/dead verification
testing of bacteria with MgO-Cl 2 and Immunoliposome-antibody complexes. Before any
cytoxitiy testing was performed, the MgO-Cl2 was tested for the presence of Chloride
ions. The Silver nitrate testing was the first assay performed to determine the presence of
chlorine within the nanoparticles. When the reactant, silver nitrate, was dispensed into
each sample prepared, a brown precipitate color change was observed in de-ionized
water. A typical positive identification for chlorine ions with the silver nitrate reagent
produces a white precipitate. Although with our samples a brown precipitate occurred
that could be attributed to the high levels of magnesium with MgO-Cl2 nanoparticles.
86
Furthermore, the results obtained provided substantial evidence indicating that the sample
of MgO-C1 2 obtained from Nanomat Inc. contained chlorine.
When attempting to use the silver nitrate assay with the liposomes solution to
determine the concentration of the MgO-C1 2 encapsulant, a slight dilemma occurred. The
buffer reacted with silver nitrate producing a white precipitate. So the silver nitrate assay
could not be performed to identify the presence of MgO-C1 2 within the liposomes.
An additional assay was performed attempting to determine the concentration of
MgO-C1 2 within the liposome solution. An absorbance scan reading of the MgO-Cl2
nanoparticles suspended in de-ionized water was performed with the Cary UV-Vis. The
results were analyzed and suggested that the MgO-Cl 2 absorbance spectrum has a slight
peak at 259nm, which continues do a steady straight line on all absorbance
wavelengths. Thus, the absorbance characteristics of MgO-Cl 2 cannot be used to identify
the concentration of MgO-Cl2 within the liposome. So, future independent assay will
have to be developed to determine the concentration of MgO-C1 2.
A series of control tests were performed to determine the nominal concentration of
MgO-C1 2 necessary to neutralize bacteria in different environments. The first bacterial
cyto-toxici test was performed with fresh B. cereus bacteria suspension cultures
incubated with various MgO-C1 2 concentrations for 24 hours. After several MgO-C1 2
concentrations were incubated within the bacterial culture suspension, sample aliquots of
each sample were plated into independent agar plates, and incubated for a day. The
following day, the plates were observed for bacteria colonies growth, which occurred in
every plate except for sample (a) and (b), corresponding to MgO-Cl 2 concentration of 1
mg/ml and 0.5 mg/ml. Note, after 24 hours of bacteria and MgO-Cl2 incubation, a strong
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chlorine odor was apparent in conical tube A and B. So from the observed results, the
optimum concentration of MgO-Cl 2 need to neutralize bacteria in suspension would be 1
to 0.5 mg/ml. Also, the bacteria conical tube with a concentration of 0.35 mg/ml still
achieved bacteria growth, which is the same concentration theoretically encapsulated
within the liposomes. So theoretically from these results it suggested that bacteria
neutralization in a sample of bacteria suspension should readily occur if MgO-C1 2
concentration encapsulated within the liposome.
Additional control test were performed with bacteria in different environments
with the neutralizing Agent, MgO-C 2 . One test was the Bioflm assay I and the other test
was Halo test, which were both performed with various Bacillus bacteria strains with
MgO-C 2 . The biofilm assay I was performed with three bacillus strains and treated with
various concentrations of MgO-C1 2. Interesting, all the bacteria strains that were treated
with v ious MgO-Cl 2 concentrations achieved bacteria growth.
One reason for bacteria growth in Biofilm I could be attributed to bacteria biofilms
formation occurring on the bottom of the PVC flat plates. The issue with this assay is
that the treatment (MgO-C1 2) is administered on the top of the biofilm. So bacteria can
still be viable on the very bottom of the plates, since MgO-Cl 2 penetration does not occur.
Also, since the bottom of random wells were scraped and plated onto agar plates to test
the effectiveness of the assay, viable cells can exist. Therefore, bacteria growth may have
resulted from error in technique.
As a result of this variability a second biofilm assay referred as the MBEC assay
was performed, which is less susceptible to technique error, in regards to bacteria biofim
assay. These MBEC biofilms are created on Pegs located on the well plate lid, and are
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released when sonicated. So the MgO-Cl2 nanoparticle is incubated within a
homogenous bacteria solution. Thus, it is a better determinant of bacteria growth or
neutralization via MgO-C1 2 n oparticles.
The MBEC biofilm study results differed from the previous results attained from
bacteria MgO-Cl 2 (neat) incubation. When three bacteria strains were treated with
various MgO-Cl2 concentrations in the MBEC study, observations varied with each
bacterium strain. Generally, all three bacteria strains had the highest bacteria
neutralization achieved with 0.5 mg/ml of MgO-C1 2 . When the individual bacterium
strain was examined, it was found that particularly B. subtilis had the second highest
neutralization achieved with MgO-C1 2 concentration of 0.35 mg/ml. This is particularly
important because the theoretical concentration of MgO-C1 2 within the liposomes was
assumed to be 0.35 mg/mi. On the contrary, both bacteria strains (B. thuringiensis and B.
cereus) had the second best bacteria neutralization at concentration of 0.125mg/ml and
0.0625 mg/mI. So the neutralizing effect of MgO-Cl2 differed when treated in biofilms
and bacteria cells suspensions.
When statistical analysis was performed on these three bacteria strains the p-value
obtained concluded that the two statistical factors, formulations, bacteria, and the
interaction were significantly different. So the MgO-Cl 2 formulations had a different
reaction with different bacteria strains, and that each bacterium examined from the same
genus does not exhibit the same reaction to the neutralization agent. Since, these bacteria
strains share very similar properties, it was suggested that similar killing effect was
supposed to be seen with all MgO-C1 2 formulations. Because the statistically results
obtained contradicted this hypothesis, it can be stated that MgO-Cl 2 could have a different
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killing effect on different bacteria strains, or the variability seen could be attributed to
wide distribution of MgO-Cl 2 particle size.
Currently, there is not an assay to quantitatively determine the concentration of
MgO-Cl2 within the liposomes, but a correlation between liposome and bacteria death can
be determined. For this reason, the MBEC assay was performed with B. cereus and
treated with the liposome samples experimentally created. After 24 hours, each
individual well was examined for bacteria growth. The experimental results obtained
with this bacterium assay gave a prediction of the neutralization property of the MgO-Cl2
and liposome formulation in bacteria biofilm neutralization. Some variability occurred
within the experimental results, for example, bacteria growth was attained after treatment
of the biofilm with liposome samples 16, 17,19, and 23, which produced bacteria growth
on average 1/3 of the time. Nonetheless, in the MBEC assay bacteria growth was
inhibited by the three liposome samples, which all had similar results when examined
under flow cytometry. The empty liposome sample 19 when examined under flow
cytometry achieved bacteria killing; this indicates that this control must have been
contaminated with MgO-Cl2. Furthermore, the best liposome sample that showed
bacteria neutralization was achieved by sample 16, which was observed with this MBEC
biofilm.
Moreover, the goal of this MBEC assay was used to determine if altering the
concentration of cholesterol within the lipid bilayer would achieve faster bacteria
neutralization. The results achieved from the original liposomes formulation with
cholesterol, and without cholesterol within the lipid membrane had similar effect on
killing the bacteria biofilms. So the actual significance of cholesterol within the lipid
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bilayer in releasing the encapsulant MgO-C1 2 could not be strongly concluded. From the
experimental results it could not be stated that the cholesterol concentration was
significant. In order to gain a better understanding on the cholesterol role in liposomal
encapsulant releasal, further studies would have to be assessed.
The results of the MBEC biofilm assay when exposed to different liposome
formulations samples showed bacteria growth inhibited in the presence of these
liposomes. From the MBEC assay, it was clearly seen that some liposome samples were
more efficient then other in the treatment of biofilms, but from the p-values obtained it
confirmed that the formulations were significantly different in terms of bacteria growth
inhibition. Therefore, our finding suggest that the cholesterol concentration within the
lipid bilayer did not produce a significant killing effect, but again further studies would
have to be performed to determine if cholesterol plays a direct role in bacteria
neutralization.
Additional evidence of the interaction of the bacteria cells with the liposomes was
apparent from e fluorescent micrographs. The images showed large quantities of the
Immunoliposome-nanoparticle complex interacted with the bacteria, and as the liposomes
surrounded the bacteria, bacteria death was increased. Also, it was evident that the
nanoparticle-antibody complex did adhere to the bacteria cell wall. The positive
indication of the nanoparticle-antibody complex attachment indicates that complex can be
used to detect the bacteria. Also, the increased bacteria occurred when liposomnes
surrounded bacteria, indicating that liposomal encapsulant is released, and the direct
contact with MgO-C 2, close proximity is responsible for bacteria death.
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Fluorescent microscopy with fluorescent dyes was used to provide additional
evidence of the neutralization power of both the liposomes and MgO-C1 2 alone. The
bacteria sample B. cereus was treated with 2 mg/ml of MgO-C1 2 and stained with Syto-9
and Ethidium homodimer-1. From the images obtained, it showed that when the bacteria
were in immediate contact with MgO-C1 2 death occurred slowly. This is evident by a
strong population of green stained live bacteria with small amount of dead cells. It was
observed that when the bacteria cells were slowly dying they were transforming from
green (live) to red (dead). This same behavior was apparent when B. subtilis was
interacted with Irmunoliposome-nanop ticle complex. At time=30 minutes a strong
presence of live bacteria cells highly fluorescent in blue were visualized, and as the
incubation time was increased, a dramatically shift was observed to the red cells (dead).
After two hours, the bacteria cells were all bright red. Similar results were obtained
when the same samples were analyzed under flow cytometry, which occurred after two
hours of incubation.
The preliminary flow cytometry results obtained with B. subtilis and the
Immunoliposome-nanoparticle complex were promising. These samples were incubated
with Syto-9 and Ethidium homodimer-1 and were examined using the fluorescent
property of the nanoparticle and dyes in determining cell viability. The shift in
fluorescence observed from green (Syto-9) to red (Ethidium homodimer-1) occurred
during bacteria death.
When B. subtilis and the immunoliposome-nanoparticle complex were initially
tested, an interaction with the bacteria was seen on the flow c ometer by triggering the
fluorescence of the nanoparticle, shown in the FL2 filter. A minimum amount of dead
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cells was viewed at time=0, but as the bacteria and Immunoliposome-nanoparticle
complex exposure time were increased a visible shift in fluorescent from green syto-9 to
deep red from Ethidium homodimer-1 was viewed in FL3 filter. So from these
preliminary results, it is understood that the maximum bacteria neutralization was
achieved after 2 hours of bacteria incubation with the Immunoliposome-nanoparticle
complex, indicating that a time factor in neutralizing the bacteria exists with this new
assay. Since a fluorescent cross talk may have occurred with the Syto-9 fluorescent dye
and the streptavidin-nanoparticle, future experiments were performed with only Ethidium
homodimer-1.
The final flow cytometry testing was performed with Bacillus cereus (closest relative
to B. anthracis) and the immunoliposome-nanop ticle samples. The initial testing was
performed to determine, if the nanoparticle-antibody complex could be used to detect and
neutralize bacteria. So, the detection portion was subdivided into two main categories,
dependent of the conjugated fluorescent nanoparticle-antibody complex, 10 and 11.
These samples were analyzed at two intervals, at time=0 and time=2 s to detect the
bacteria samples. The fluorescence of the nanoparticles was triggered, and the results
were obtained in histograms in the FL2 filter.
The results obtained from complex 10 all showed bacteria detection occurred when
introduced to the bacteria cultures. All the samples at time=0 had almost identical
detection histograms. As the time progressed and the liposomes samples were
introduced, two samples dissociated from the bacterial wall, indicating bacteria detection
decreased after 2 hours. This dissociation occurred with the samples 13-10 and 17-10.
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Interesting the lipid film sample Formulation (d) and (a) both had only one sample with
bacteria dissociation.
The histograms of complex 11 were examined at two specific intervals. When the
complex was analyzed with B. cereus, bacteria detection occurred immediately. The
detection of the bacteria is apparent by a shift to the right in the histogram within the
gated region. When this same gate was examined after 2 hours, similar histogram
profiles were obtained, except sample 22-11 had high bacterium dissociation.
One of the hypotheses attempted to determine if optimizing by using different types
biotin linker on the lipid membrane could up regulate bacteria detection. From the results,
trends suggest that our hypothesis was not supported. Formulation (d), corresponding to
samples 12, 17,19, and 21, did not show substantial increase in detection when compared
to Formulation (a). Sample 17 showed dissociation after 2 hours of bacteria incubation,
this was not observed in other complex 10 samples. Dissociation in complex 11 occurred
with Sample 22 corresponding to Formulation (b), containing double the concentration of
cholesterol.
So from our findings currently suggests that there is no correlation between liposome
formulation and bacteria to increases bacteria detection, since reduced bacteria detection
occurred with one sample of each of the four-liposome formulation. Therefore because
of insufficient evidence from the experiments performed, no assessment could be made to
either accept or deny the notion that using a different biotin linker in the lipid membrane
could increase bacteria detection.
In addition, in order to clearly determine if altering the type of biotin within the lipid
membrane has a direct correlation with detection, a new fluorescent nanoparticle would
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have to be used. Since the fluorescent profile of these nanoparticles have a very broad
excitation and emission spectrum, it was challenging to obtain a strong fluorescent signal.
The use of brighter nanoparticles with a narrow fluorescent spectrum would better assist
in detecting the presence of bacteria by flow cytometry, and determine if the type of
biotin linker used did actually affect detection.
Bacteria neutralization with the newly created Immunoliposome-nanoparticle
complex was examined with flow cytometry. All the liposome samples created were
analyzed immediately with a red fluorescent membrane impermeable dye, Ethidium
homodimer-1. The Immunoliposome-nanoparticle complex and bacteria samples were
analyzed individually, and the data histograms were overlaid and plotted. The first set of
liposome samples that were analyzed belonged to Formulation (a), sample 16-10,14-
10,15-10,16-10,18-11. When these samples were examined at time=0, they all showed
similar histogram profiles, except for sample 16, which had at time=0 had a histogram
peak very close to the ethanol treated dead control region. Both samples 14-10 and 15-10
had the identical histograms in the MgO-Cl2 neutralized gated region. Also, samples 13-
10 and 18-11 both had similar neutralizing affect on the bacteria sample; note sample 18-
11 was the control sample.
The second Formulation (b) samples were interacted with the B. cereus with flow
cytometry, at two intervals. The data histograms were overlaid and the neutralization
effectiveness was analyzed. From the histogram data, it showed that the greatest killing
effect occurred with the liposome sample 20-11 at time=0 with a majority of the cells in
the ethanol neutralized controlled region. As the incubation time was increased, the
killing effect increased and a sharp histogram appeared further from the ethanol treated
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bacteria cell gate. However, the rapid and effective killing effect of sample 20-11 was
not observed with sample 22-11. So it is not clear if the formulation was responsible for
instant bacteria death. So a new liposome sample with the same formulation would have
to be created and re-analyzed in order to create a strong statement on this formulation.
The third lipid Formulation (c) was observed with flow cytometry to determine the
effectiveness of the liposomes, in neutralizing the bacteria sample. When this sample was
analyzed, it was observed that the histogram showed a broad distribution within the
MgO-Cl2 neutralized gated region at time=0. As the incubation time increased with the
liposome sample 23-11 and B. cereus a slight histogram shift towards the ethanol-killed
bacteria gated region was observed. The widespread broad histogram of the liposomes
with bacteria showed that although the killing effect was not as substantial as observed by
sample 20-11, these bacteria cells were not content.
The Formulation (d) was interacted with B. cereus and was monitored with flow
cytometry. The histogram data obtained were analyzed and the samples 12-10,18-11, and
17-10, all showed similar results with histograms in the live region. Nonetheless, sample
21-11 showed a greater shift towards the ethanol dead gated region after 2 hours of
bacteria sample incubation. The results obtained suggests that the greatest killing effect
occurred with the sample 21-11, which was represented by a broad histogram after two
hours of incubation that spilled over to the ethanol treated region.
From all the data obtained, we can suggest that the lipid composition of the
liposomes does have an affect in neutralizing the bacteria. The liposome that had showed
the greatest killing effect occurred with sample 16-10 (a), 20-11(b), 23-11 (c), and 21-11
(d). The greatest killing effect of these four was observed with 20-11. Thus, we cannot
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make a clear indication if the concentration of cholesterol within the lipid membrane can
account for the rapidly neutralizing effect of this liposome sample. These samples would
have to be analyzed further to determine if cholesterol is important component for
releasal of MgO-C12 within the liposome.
6.0 SUMMARY AND CONCLUSION
The experimental results obtained from this thesis can be used to formulate strong
statements about the effectiveness of the novel detection and neutralization assay for
bacteria biohazards. First, it can be stated that this newly developed assay can be used
not only to neutralize bacteria, as seen from the flow cytometry results, but also in the
treatments of bacteria biofilms. The flow cytometry results indicated that the streptavidin
nanoparticle-antibody complex adheres rapidly and effectively to the bacterial cell
membrane producing a distinct fluorescent signal, indicating this new assay can be used
to detect the presence of bacteria biohazards.
Furthermore, bacteria neutralization was enhanced by liposome drug delivery. From
o experimental results, it was determined that the actual concentration MgO-Cl2 within
the liposomes was not a critical factor in neutralizing the bacteria. The actual delivery
density of these nanoparticles introduced to the surface of the bacteria was more effective
with a lower concentration, then, a higher concentration of pure nanoparticles incubated
with the bacteria. This could have attributed to the bactericidial properties of the surface
area of the nanparticles in interacting with the bacterial cell membrane. So the
encapsulation of these nanoparticles within the liposomes resulted in a higher bacteria
and biofilm neutralization.
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So the drug delivery of the neutralization agent is not completely dependent on the
concentration but the density within the liposomes that target the bacteria biohazards.
Previous finding suggested that when these nanoparticles are in close proximately to each
other, they fo clusters that attack aggressively the cell membrane with high chlorine
activity. This could be attributed to the increased cell death with minimal drug
concentration. Also, since these liposomes are modified with fluorescent nanoparticles-
antibody complex the neutralization agent are immediately delivered at very close
proximately to the bacteria cell wall, this is attributed to the antibody attachment to the
antigen on the bacteria surface.
So this novel detection and neutralization assay can be used on bacteria and spores
that have germinated when introduced to a nutrient environment. This statement is
supported from results obtained in flow cytometry, since the bacteria samples used were
within culture media. So the environment does not affect the assays effectiveness, and
can be used on any surface to treat bacteria in any environment.
In order to increase detection time and achieve a time sensitive assay, a
fluorescent streptavidin nanoparticle with a tighter excitation and emission peak should
be utilized. By using a nanoparticle with a tighter excitation/emission spectrum will
allow for this assay to be tested with several cytotoxity fluorescent dyes. This flexibility
could assist in producing a multirange peak from not only the fluorescent dyes but the
nanoparticles. This could in results assist in achieving a quicker and cleaner positive
identification for the detection and neutralization of the assay with additional Anthrax
models.
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APPENDICES
Liposome Formulation (a)
1. Lipid solution: Add 7.5 mg Peg2000-Biotin +17.5 mg Phosphatidylcholine +
13.11 mg Cholesterol to a round bottom flask with 5 ml of chloroform.
2. Place the flask on the Rotovap evaporator until all the chloroform has evaporated
and a film is obtained approximately 1.5 hr.
3. Place the lipid film in a vacuum pump under -20 0C overnight
4. Rehydrate lipid film with 7 ml of HEPES solution of 3 mm Trehalose solution
with 0.25 mg MgO-C1 2 .
5. Freeze dry lipid film 10 times under liquid nitrogen
6. Soak membrane filter in HEPES Solution
7. Assemble the Extruder apparatus with soaked filter and membranes
8. Heat Extruder apparatus until temperature is constant 62 F
9. Draw 1ml of sample with the extruder syringe
10. Circulate the sample for a total of 10 times alternating syringes.
11. Decant liposome and non-liposome samples into freezer vials and freeze under -
800 C
Liposome Formulation (b)
1. Obtain a round bottom flask and coat with chloroform solvent.
2. Create a lipid solution composed of: 7.5 mg (Biotin Capped DSPE-Peg2000), 26
mg (Cholesterol), 46 mg (egg Phosphatidylcholine) dissolve in 5 ml of Choloform
Solvent
3. Place the round bottom flask on Rotovap evaporator. Set the conditions of the
evaporator equipment to the following:
a. Water bath temperature to 390 C
b. Water Circulator 14*C
c. Flask under Vacuum
d. Rotation speed 155rpm
4. Allow the flask to rotate for 1 ho or until the solvent has completely evaporated
5. Once a film has been obtained, remove flask from the Rotovap. Dip the Flask in
liquid nitrogen for approximately 1 minute.
6. Then place the frozen film in the lypholizer, and allow the film to dry overnight.
7. The following day pre-set the temperature on the Rotovap to the following:
a. Water bath 55*C
b. Water Circulator 14 C
8. Dispense 7 ml of 3 mM Trehalose HEPES solution into lipid film containing
round bottom flask
9. Add 2.5 mg MgO-C1 2 to flask.
10. Place the flask into the Buchii Rotovap. Adjust the angle of the rotovap to ensure
full submerge in of the lipid film in the buffer. Set the rotation speed to 165rpm
and allow the film to dissolve for approximately 1 hour. \
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11. 'le the lipid film is rotating, so the extruder membranes in HEPES buffer.
Assemble Mini extruder and place it onto a heating block. Set the temperature of
the heating block to low to achieve a steady 620 C.
12. Once the lipid film has dissolved, freeze thaw the lipid sample under liquid
nitrogen for 5 times.
13. Once the extruder has reached desired condition. Extract I ml of lipid solution
and place it to one side of the extruder apparatus. Place an empty 1ml syringe in
the opposite side of the extruder.
Pass through lipid solution through the extruder membranes a total of 10 times alternating
sides. Dispense the liposome solution into a glass container, and store sample at -200 C
Liposome Formulation (c)
1. Obtain a round bottom flask and coat with chloroform solvent.
2. Create a lipid solution composed of: 7.5 mg (Biotin Capped DSPE-Peg2000), 46
mg (egg Phosphatidylcholine) dissolved in 5 ml of Choloform Solvent
3. Place the round bottom flask on Rotovap evaporator. Set the conditions of the
evaporator equipment to the following:
a. Water bath temperature to 39 C
b. Water Circulator 14 C
c. Flask under Vacuum
d. Rotation speed 155rpm
4. Allow the flask to rotate for 1 ho or until the solvent has completely evaporated
5. Once a film has been obtained, remove flask from the Rotovap. Dip the Flask in
liquid nitrogen for approximately 1 minute.
6. Then place the frozen film in the lypholizer, and allow the film to dry overnight.
7. The following day pre-set the temperature on the Rotovap to the following:
e. Water bath 55'C
f. Water Circulator 14*C
8. Dispense 7 ml of 3 mM Trehalose HEPES solution into lipid film containing
round bottom flask
9. Add approximate MgO-C1 2 concentration to flask (2.5 mg).
10. Place the flask into the Buchii Rotovap. Adjust the angle of the rotovap to ensure
full submerge in of the lipid film in the buffer. Set the rotation speed to 165rpm
and allow the film to dissolve for approximately 1 hour. \
11. While the lipid film is rotating, soak the extruder membranes in HEPES buffer.
Assemble Mini extruder and place it onto a heating block. Set the temperature of
the heating block to low to achieve a steady 62'C.
12. Once the lipid film has dissolved, freeze thaw the lipid sample under liquid
nitrogen for 5 times.
104
Liposome Formulation (d)
I. Obtain a round bottom flask and coat with chloroform solvent.
Create a lipid solution composed of: Biotin-DSPE, DSPE-PEG2000,
Phosphatidylcholine, and Cholesterol (5 mg, 2.5 mg, 34 mg, 9.7 mg)
2. Place the round bottom flask on Rotovap evaporator. Set the conditions of the
evaporator equipment to the following:
a. Water bath temperature to 39'C
b. Water Circulator 14 0 C
c. Flask under Vacuum
d. Rotation speed 155rpm
3. Allow the flask to rotate for 1 hour or until the solvent has completely evaporated
4. Once a film has been obtained, remove flask from the Rotovap. Dip the Flask in
liquid nitrogen for approximately 1 minute.
5. Then place the frozen film in the lypholizer, and allow the filn to dry overnight.
6. The following day pre-set the temperature on the Rotovap to the following:
g. Water bath 55 C
h. Water Circulator 14 C
7. Dispense 7 ml of 3 mM Trehalose HEPES solution into lipid film containing
round bottom flask
8. Add approximate MgO-C1 2 concentration to flask (2.5mg).
9. Place the flask into the Buchii Rotovap. Adjust the angle of the rotovap to ensure
full submerge in of the lipid film in the buffer. Set the rotation speed to 165rpm
and allow the film to dissolve for approximately 1 hour. \
10. While the lipid film is rotating, soak the extruder membranes in HEPES buffer.
Assemble Mini extruder and place it onto a heating block. Set the temperature of
the heating block to low to achieve a steady 62 C.
11. Once the lipid film has dissolved, freeze thaw the lipid sample under liquid
nitrogen for 5 times.
Separation of low molecular weight solutes from liposomes by centrifugation
through a mini column
Equipment:
Centrifuge with swinging bucket rotor
Barrels of 5ml plastic syringes
Sephadex G50
Glass wool
HEPES Buffer
Procedures:
1. Swell Sephadex G-50 in HEPES buffer
2. Place small amount of glass wool in a beaker containing HEPES buffer
3. Place the soaked glass wool into plastic syringe and press firmly with plunger to
pack tightly glass wool
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4. Degas sephadex G-50 and pour into the syringe
5. Place the mini column into a 15 ml conical tube, and place inside the centrifuge.
6. Spin for 3 minutes at 1 Og to remove excess buffer from the gel
7. Transfer syringe into a new conical tube and apply 1 ml of liposome sample to the
column
8. Spin the column at 50g for 10 minutes
9. Then spin the column for 3 minutes for 1 000g to expel the liposome material from
the column into the test tube
10. Discard the column and store purified liposome sample in -20 C freezer
Synthesis of streptavidin-conjugated mAb
1. Dissolve the antibody to be modified at a concentration of 1-10mg/ml in .1 M
sodium phosphate, 0.15 M NaCl, pH 7.2, containging 10 mM EDTA.
2. Add 2-iminothiolane ( Traut's reagent: Sigma) to this solution to give a molar
excess of 40 X over the amount of antibody present. The greater the molar excess
of traut's reagent added, the higher level of thiolation and the greater the
incorporation of Maleimide-Streptavidin.
3. React for 30 min at 37 *C or 1 hour at room temperature
4. Purify the thiolated antibody by gel filtration using a desalting matrix such as
sephadex G-25. Perform the chromatography using 0.1 M sodium phosphate,
0.15 M NaCl, pH 7.2, containing 10 mM EDTA as the buffer. To obtain efficient
separation between the reduced antibody and excess reductant, the sample size
applied to the column should be at a ratio of no more than 5% sample volume to
the total column volume. Collect 0.5 ml fractions and monitor for proteins at 280
nm. To monitor the separation of the second peak (excess Traut's reagent), the
BCA protein assay reagent (Pierce). The BCA- copper reagent reacts with both
the protein fractions and the sulfhyd 1 groups of MEA to produce a colored
product.
5. Dissolve the streptavidin (2 mg, 33 nmol) in 200 1 of 0.1 M PBS ( 100 mM
phosphate/150 mM sodium chloride, pH 7.4) and activate by 20:1 Molar excess of
m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS).
6. Incubate for 1 hour at 20*C with gentle shaking.
7. Purify the mixture by Sephadex G-75 gel-filtration chromatography and UV
detection at 280 nm.
8. The thiolated antibody is conjugated with the activated streptavidin at a molar
ratio 1:3 (antibody:streptavidin).
9. Incubate overnight at 20*C with gentle shaking.
10. Purify the reaction product with Sephacryl-200 gel filtration chromatography and
mAb-streptavidin containing samples detected by measuring the absorbance at
280 nm.
11. Store the samples in 0.01 M Pbs at -20*C
12. BCA protein assay reagent (Pierce) with BSA as the reference for protein
concentration. The BCA- copper reagent reacts with both the protein fractions
and the sulfhydryl groups of MBA to produce a colored product.
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Centriprep 30 Procedure Protocol
1. Removal of Glycerin in membranes
a. Add 15 ml of Buffer in the sample container.
b. Centrifuge the Centriprep 30 at 3000 G
c. Decant the solution from the filtrate cavity.
d. Re-suspend the membranes with 5ml buffer
e. Centrifuge the centriprep filter again at 3000 G for 10 minutes to remove
all traces of glycerin
f. Decant the buffer in the filtrate cavity.
g. Leave the buffer in the sample cavity until it is ready to be used with
samples. Once the membranes are soaked it must be used immediately.
2. Sample filtration (Streptavidin-MBS)
a. Decant buffer from the sample cavity.
b. Add the sample to be purified in the sample cavity. The maximum
volume that can be placed is 15 ml.
c. Place the filtrate collector inside the sample cavity and make sure it is lock
and secure.
d. Insert the Centriprep device into the centrifuge and counterbalance with a
weigh balance.
e. Spin the Centriprep device at the appropriate g-force until the fluid levels
inside and outside the filtrate collector equilibrate.
i. Biofuge Primo up to 3000 x G without lid
f. Remove the device from the centrifuge and snap off the air cap seal.
Decant the filtrate.
g. Loosen the twist lock cap and remove filtrate collector.
h. Add 2 ml of IEPES buffer in the sample cavity.
i. Push filtrate collector against buffer to release the nanoparticles on the
surface of the membranej. Decant purified sample into a 1 5m conical tube and store in the
refrigerator.
Protocol for Rea Assay Standard
Materials:
BCA kit
96-well plate
Tecan Genios Spectrophotometer
Procedures:
1. Take the BSA (2 mg/ml) capsule out of the box. Carefully break the glass tube
and transfer the albumin into a 1.5 eppendorf tube.
2. Then perform dilutions of the standard following the Table below.
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Vial Volume of Dilutent p1 Volume of BSA [d Final Concentration
/ml
A 0 300 2000
B 125 375 1500
C 325 325 1000
175 175 750
325 325 500
325 250
00 325 125
H_ 400 100 25
I 400 0
3. Prepare the working reagent by adding 1 ml of reagent B and 50 ml of reagent A.
4. Pipette 25 pl of each standard and dispense into ricrotiter plate well.
5. Add 200 1 of the working reagent to each well.
6. Place the standard in and 37*C incubator for approximately 2 hours.
7. Take the plate out of the incubator and allow the plates to cool down to room
temperature.
8. Then load the plate into the Tecan spectrophotometer. Set the setting to shake for
30 seconds.
9. Read the absorbance of the plate at 595nm and 520nm.
10. Record the data and subtract the values obtained from the bla from each
individual sample or unknown.
11. Perform a standard curve to determine protein concentration of each unknown
sample.
Bacteria Inoculation
Scope and Applicability
Inoculation is necessary to grow out a population of bacteria. Using a portion of a single
colony, a population of bacteria on the order of 10 bacteria, depending on the doubling
time, can be obtained
Summary of Method
Use aseptic technique to add a sample of bacteria to a 125 mL flask containing LB
media. Use a loop to remove a single colony from a culture dish. Dip the tip of the loop
containing the colony into the flask containing the LB media. Mix, and incubate the flask
as prescribed for the strain it contains.
Definitions
Inoculation: seeding a container of nutrients with a small number of bacteria to be grown
out
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Equipment and Supplies
Auto pipette
10 mL of recently sterilized LB media
10 mL pipette tip
125 mL Erlenmeyer Flask
Bunsen burner
"Loop"
Culture dish of bacteria strain
Procedure
The following is explicit example of aseptic technique on the desktop:
1. Label a sterile 125 mL flask with name, date, and strain to be inoculated with.
2. Light the Bunsen burner, and keep all materials as close as safely possible to the
burner (to minimize risk of contamination).
3. Loosen the lid of the LB vessel.
4. Loosen the stopper of the empty flask.
5. Open the bag of sterile loops, and set back on the desk.
6. Open the insertion end of the 10 mL glass pipette wrapper just enough to insert
the pipette into the auto pipetter. Do not touch any part of the pipette.
7. Flame the pipeter by flaming the length of the glass for a total time of 2 seconds.
8. Keeping the pipette close to the flame, either:
9. With the other hand, uncap the vessel of LB, then flame the cap quickly and set it
down open side up. Or
o With the pin of the hand with holding the autopippete, uncap the vessel
of LB media, and hold the cap with that pinky, taking care not to touch the
rim of it or the underside to anything. Flame the under half of the cap.
10. Flame the neck and opening of the LB vessel for 2 seconds.
11. Keeping the pipette within 20' of vertical, withdraw 10 mL of LB from the LB
vessel.
12. Re-flame the vessel as before.
13. Flame the underpart of the vessel cap.
14. Re-cap the vessel, with either the hand holding the pippete or the other hand, as
appropriate.
15. Taking care to keep the pipette within 200 of vertical, grasp the stopper flask in
the other hand.
16. Using the pinky of the hand holding the auto pipette, remove the foam stopper of
the flask, and hold it with that pinky. Be sure not to allow the bottom half of the
stopper to touch anything.
17. Flame the neck and top of the flask, as done previously with the LB vessel.
18. Without touching the pipette tip to the flask, deposit the 10 mL of media held in
the pipette.
19. Flame the neck and top of the flask as before.
20. Recap the stopper to the flask.
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21. Remove the glass pipette from the autopipetter and place the glass in the disposal
container.
22. Re-examine the agar plate for a single colony, and note it by memory.
23. Place the plate back on the desk.
24. Remove a loop from the loop bag. Do this by:25. Grasp the bag with loops in one hand.
26. Grasp the middle of a single loop with the other hand and push it out through the
opening of the bag, until the middle shaft of the loop is exposed. Be sure not to
allow another loop to become exposed to any extent.
27. Taking care not to touch the tip of the loop with anything, grasp the shaft of the
loop and pull it from the bag.
28. Put the bag of loops back on the desk.
29. Grasp the top plate of the agar plate (containing the agar) with the hand not
holding the loop.
30. With the loop tip at a 45 angle, remove the single colony noted before from the
agar. Do this quickly, and with a sweeping motion just enough to carry off the
colony (or at least a significant portion of the colony). Take special care not to
include any portion whatsoever of any other colony in the sweep.
31. Re-cover the plate.
32. Using the hand holding the loop, remove the stopper to the flask as before, with
the pinky.
33. Flame the neck and top of the flask, as before.
34. Taking care not to touch the shaft of the loop to anything, including the flask,
quickly insert the tip of the loop into the flask opening, and allow the tip to touch
the media.
35. Re-flame the flask.
36. Re-cap the flask.
37. Incubate the flask as required for the strain it contains.
SOP Spectrophotometry
Summary of Method
Set the spectrophotometer to read a sample at the required wavelength of the substance
being tested. Read a blank with the machine. Then determine the absorbance of the
experimental sample.
Equipment and Supplies
* Spectrophotometer
* 1 mL cuvet
* Sample of bacteria
* 1,000 [L pipette
* 1,000 piL pipette tip
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Procedure
1. Using the 1,000- p pipette, add 1 mL of culture minus bacteria (a blank) to a 1
mL cuvet. Make sure not to touch below the top half of the cuvet.
2. In the same manner, add 1 mL of sample culture to another cuvet (experimental
sample).
3. Insert the blank cuvet into the cuvet holder with the textured sides of the cuvet
facing the sides of the square opening.
4. Set the frequency on the machine to OD 600. This is the frequency of absorption
for most bacteria studied in the lab.
5. Push the "Read Blank" button.
6. Remove the bla cuvet and set aside.
7. Insert the experimental cuvet into the cuvet opening of the machine, in the same
orientation as before.
8. Push the "Read Sample" button.
9. The spectrophotometer will then read the sample and display its absorbance and
concentration of bacteria. Note these values. The machine will also store the
value of all readings taken until the memory is cleared. (see note below)
Bacteria and MgO-C1 2 Tes ing
1. Obtain five 5m sterile conical tubes and fill them with 50ml of sterile PBS.
2. Then prepare a variety of drug standard to be tested against the bacteria. Such as:
a. 1 mg/ml need 50mg
b. 0.5 mg/ml need 25mg
c. 0.25 mg/ml need 12.5mg
d. 0.125 mg/ml need 6.25 mg/ml
e. 0.0625 mg/ml need 3.125 mg
f. 0 mg/ml
3. Then add .5ml of bacteria cell of concentration of 105 cfu/ml to each conical tube
4. Shake each conical tube vigorously
5. Then place each conical tube in a mechanical shaker for 24 h at 370C
6. After 24 hr, extract 0.5ml out of each conical tube and dispense it into a sterile
plate with culture medium.
7. Culture the bacteria and drug sample for 48 hrs at 37*C
8 Next, count all the bacteria colonies by eye and record experimental values
9. Finally, determine the bactericidal efficacy (%) by using the following equation
Bactericidal efficacy (0) Alive number in reference xrou-alive number in experimental rou 
100
Alive number in reference group
Protocol for biofil formaton iofil Assay I
1. Strains are inoculated into LB Broth and grown overnight (ON) 1:100 dilution ON LB
culture standardized
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2. Poly vinylchloride plates inoculated with 100,1 of dilution
3. Plates placed in a Microbiological incubator at 370 C for 24hrs.
3. Added /MgO-C 2 to 96-well plates
Protocol for viewing bacteria and liposome under Fluorescent microscope testing
1. Bacteria culture were grown for 18 hr in 37*C and prepared by lance
2. Obtain a 5 ml sample of the bacteria and place in a conical tube
3. Spin the bacteria sample at 2000 X g for 15 minutes
4. Discard the supernatant and resuspend with 3 ml of sterile PBS
5. Spin the bacteria again for 2000 X g and then resuspend in PBS perform this 3
times.
6. Aliquot 200 l of bacteria and place in an 1.5 ml eppendorf tube
7. Add 100 I of liposome containing MgO-Cl2
8. Gently mix the sample for about one minute. Then swab a small amount of the
sample onto a glass slide and view under the microscope. Take a picture of the
sample
9. After viewing add 3 Il of propidium iodine stain to the bacteria liposome sample
10. View again under the fluorescent microscope and view if the fluorescent is
detected.
11. Repeat steps 6-10 again but instead of using liposomes add liposome-antibody-
streptavidin, non-liposome, antibody-nanoparticle, and MgO-Cl2.
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